

# Effects of long-term culture on the biological characteristics and RNA profiles of human bone-marrow-derived mesenchymal stem cells

Shan Wang,<sup>1,6</sup> Ziming Wang,<sup>2,6</sup> Hongjun Su,<sup>3,6</sup> Fenglei Chen,<sup>2</sup> Mengjun Ma,<sup>2</sup> Wenhui Yu,<sup>2</sup> Guiwen Ye,<sup>4</sup> Shuizhong Cen,<sup>5</sup> Rujia Mi,<sup>1</sup> Xiaohua Wu,<sup>3</sup> Wen Deng,<sup>3</sup> Pei Feng,<sup>3</sup> Chenying Zeng,<sup>1</sup> Huiyong Shen,<sup>2,4</sup> and Yanfeng Wu<sup>1</sup>

<sup>1</sup>Center for Biotherapy, Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen 518033, P.R. China; <sup>2</sup>Department of Orthopedics, Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen 518033, P.R. China; <sup>3</sup>Center for Biotherapy, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou 510120, P.R. China; <sup>4</sup>Department of Orthopedics, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou 510120, P.R. China; <sup>5</sup>Department of Orthopedics, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, P.R. China

**Expansion *in vitro* prior to mesenchymal stem cells (MSCs) application is a necessary process. Functional and genomic stability has a crucial role in stem-cell-based therapies. However, the exact expression and co-expressed profiles of coding and non-coding RNAs in human bone marrow (BM)-MSCs *in vitro* aging are still lacking. In the present studies, the change of morphology, immunophenotype, and capacity of proliferation, differentiation, and immunoregulation of MSCs at passage (P) 4, P6, P8, P10, and P12 were investigated. RNA sequencing identified that 439 mRNAs, 65 long noncoding RNAs (lncRNAs), 59 microRNAs (miRNAs), and 229 circular RNAs (circRNAs) were differentially expressed (DE) in P12 compared with P4, with a similar trend in P6. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA) identified several significant biological processes and pathways, including binding, ossification, and Wnt and PPAR signaling pathways. Interaction and co-expression/localization analyses were performed for DE mRNAs and lncRNAs, and several key lncRNAs, circRNAs, and important pathways like autophagy and mitophagy were identified in the competing endogenous RNA (ceRNA) network. Some key RNAs found in the bioinformatics analysis were validated. Our studies indicate that replicative senescence of MSCs is a continuous process, including widespread alterations in biological characteristics and global gene expression patterns that need to be considered before therapeutic applications of MSCs.**

## INTRODUCTION

Mesenchymal stem cells (MSCs) are an attractive candidate for clinical applications in cell therapy and regenerative medicine due to their self-renewal ability, multi-lineage differentiation potential, immunosuppressive properties, trophic effects, and paracrine function.<sup>1</sup> Since the discovery of MSCs in bone marrow (BM) in 1966, various tissues, including umbilical cord (UC) blood, UC, synovial membrane, adipose tissues, dental pulp, and skeletal muscle, have been reported as

sources of MSCs.<sup>2-4</sup> Among the different sources, however, BM is still by far the best characterized source of MSCs. Moreover, due to significant ethical issues and safety considerations, MSCs are seen as more feasible and advantageous in clinical applications than embryonic stem cells.<sup>5</sup> Thus, BM-MSCs have been broadly applied in the treatment of various diseases, including graft-versus-host disease (GVHD), Crohn's disease (CD), diabetes mellitus (DM), multiple sclerosis (MS), myocardial infarction (MI), ankylosing spondylitis (AS), liver failure, and rejection after liver transplantation.<sup>6,7</sup>

Conventionally, the dose for MSC transplantation is 10<sup>6</sup> cells/kg body weight, and the total number of MSCs for one patient is approximately 10<sup>8</sup> per cell therapy in clinical trials.<sup>8</sup> MSCs are a very rare population that accounts for only 0.01% to 0.001% of the cell numbers in BM.<sup>9</sup> The low frequency and lack of high homogeneity of freshly extracted MSC populations necessitates extensive *in vitro* expansion following isolation prior to various clinical applications and essential manipulation. According to the "Hayflick limit," MSCs have a limited replicative lifespan of approximately 50 population doublings in cell culture,<sup>10,11</sup> and the functions of MSCs, like proliferative, differentiated, and immunoregulatory potential, are known to change with their *in vitro* expansion,<sup>12-15</sup> a process that may have a similar mechanism to that of aging *in vivo*.<sup>16</sup> Therefore, it is important to consider the influence of *in vitro* aging on cellular characteristics when developing new MSC-based therapeutic strategies. Understanding the molecular processes controlling MSC proliferation, senescence, and

Received 23 November 2020; accepted 12 August 2021;  
<https://doi.org/10.1016/j.omtn.2021.08.013>.

<sup>6</sup>These authors contributed equally

**Correspondence:** Yanfeng Wu, Center for Biotherapy, Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen 518033, P.R. China.

**E-mail:** [wuyf@mail.sysu.edu.cn](mailto:wuyf@mail.sysu.edu.cn)

**Correspondence:** Huiyong Shen, Department of Orthopaedics, Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen 518033, P.R. China.

**E-mail:** [shenhuiy@mail.sysu.edu.cn](mailto:shenhuiy@mail.sysu.edu.cn)



commitment to specific differentiated cell lineages is not only essential for the development of therapeutic interventions but also crucial to determining the drivers and effectors of age-associated MSC dysfunction that can slow, or even reverse, age-related degenerative changes to enhance repair processes and maintain healthy function in aging tissues.

Long noncoding RNAs (lncRNAs) are a type of ncRNA greater than 200 nucleotides (nt) in length. Circular RNAs (circRNAs), a kind of ncRNA, are a large family of covalently closed ring-like RNA molecules. MicroRNAs (miRNAs) are short ncRNAs. It is known that miRNAs can induce gene silencing by binding to mRNAs, and lncRNAs/circRNAs can regulate gene expression by competitively binding to miRNAs.<sup>17,18</sup> Recently, multiple studies have demonstrated that these ncRNAs are important epigenetic regulators and are widely involved in growth, immune system homeostasis, proliferation, and differentiation and development by controlling the fate of cells, including MSCs.<sup>19–21</sup> Large intergenic nc RNAP21 (lincRNAP21) was reported to play a role in MSC senescence by interacting with the Wnt/ $\beta$ -catenin signaling pathway to attenuate oxidative stress.<sup>22</sup> However, more lncRNAs and circRNAs involved in MSC aging need to be identified/characterized. Additionally, it is not known how senescence influences the overall expression of lncRNAs and circRNAs, and the epigenetic regulation of coding genes by lncRNAs and circRNAs in MSCs still needs to be analyzed.

With this in mind, we designed a study to analyze how the morphology, immunophenotype, proliferation, differentiation, and immunoregulatory capacity of MSCs are affected by *in vitro* expansion. In parallel, we analyzed how mRNA, miRNA, lncRNA, and circRNA expression profiles change upon culturing and *in vitro* propagation. We aimed to gain insight into the molecular mechanisms underlying MSC aging, which may have an impact on the quality control of MSC preparations, and identify strategies to rejuvenate senescent MSCs to broaden the range of therapeutic applications of MSCs.

## RESULTS

### Changes in the morphological characteristics, population doublings, immunophenotype, differentiation, and immunoregulation of HBM-MSCs at different passages

A total of 20 healthy donors between the age of 20 and 30 years were selected for this study. MSCs from one donor were cultured separately as one sample. During primary culture, spindle-shaped, plastic-adherent, and fibroblast-like cells were observed around the adherent hematopoietic progenitor cells in all donor samples within the first day of culture. The cells grew, formed colonies, and appeared as a heterogeneous population of BM-MSCs at passage 0 (P0, Figure 1A), which were extended to P12 with subsequent subculture. P4 MSCs comprised a mostly pure population without hematopoietic progenitor cells. Proliferation and the number of cell population doublings (NCPD) decreased gradually in all samples over the course of long-term culture from P4 to P12 (Figures 1B and 1C). Replicative senescence led to the following previously observed typical morphological changes (Figures 1D and 1E): the cells became much larger with irreg-

ular and flat shapes, and the nuclei became more circumscribed by phase contrast microscopy. The cytoplasm became granular with many inclusions appearing as increased cell debris. The cell cycle analysis of MSCs from P4, P6, P8, P10, and P12 during long-term culture indicated that the percentages of cells in S and G2/M phases decreased gradually (Figure 1F; Table S1). Taken together, these results demonstrated the increased morphological heterogeneity and reduced proliferative capability of MSCs during *in vitro* aging.


Flow cytometric analysis indicated the presence of CD90, CD105, and CD73 expression and the absence of CD45, CD14, CD34, and human leukocyte antigen DR (HLA-DR) expression in MSCs at P4, P6, P8, P10, and P12, confirming their MSC immunophenotype (Figure 1G; Table 1). With increasing passages, the percentage of MSCs expressing CD45, CD14, CD34, and HLA-DR remained stable, while the percentage of MSCs expressing CD90, CD105, and CD73 decreased gradually, especially CD105, which was decreased from 94.05% (mean) in P4 to 47.38% in P12. These results show that the composition and expression levels of surface markers partly vary upon long-term expansion.

The potential for osteogenic and adipogenic differentiation was confirmed following standard protocols. Alizarin red S (ARS) and oil red O (ORO) staining showed that calcium deposition and fat formation were much more effective in MSCs at early passages than later passages, indicating that the osteogenic and adipogenic differentiation potential both decreased over the course of *in vitro* senescence (Figures 2A, 2B, 2D, and 2E). Furthermore, the degree of decrease in osteogenesis was much more dramatic than that in adipogenesis. Similarly, the percentage of senescence-associated  $\beta$ -galactosidase (SA- $\beta$ -gal) positive cells and the staining intensity increased in the last passages of MSCs (Figures 2C and 2F), and the relative telomere length in MSCs decreased in P12 compared with P4 (Figure 2G). These results support the notion that long-term culture has an incremental impact on the differentiation potential of MSCs, which was accompanied by deepening of SA staining and shortening of telomere length of MSCs.

The potential of MSCs at different passages to inhibit CD4<sup>+</sup> T cell and CD19<sup>+</sup> B cell proliferation was analyzed by coculturing  $\alpha$ CD3CD28-activated CD4<sup>+</sup> T cells and LPS-stimulated CD19<sup>+</sup> B cells with MSCs at P4, P6, P8, P10, and P12. The capacity of MSCs to suppress CD4<sup>+</sup> T cell and B cell proliferation decreased during prolonged culture expansion. When cocultured with P4 and P6 MSCs, activated CD4<sup>+</sup> T cells and B cells could be inhibited, while P8 and P10 MSCs almost completely lost the capacity to inhibit CD4<sup>+</sup> T cell and CD19<sup>+</sup> B cell proliferation. Moreover, P12 MSCs even enhanced the proliferation of CD4<sup>+</sup> T cells and CD19<sup>+</sup> B cells (Figures 3A–3D).

### Differential gene-expression profiles of MSCs during *in vitro* aging

A total of nine samples consisted of three MSCs at P4, P6, and P12, respectively, were subjected to whole-transcriptome RNA sequencing (RNA-seq). The mRNAs, lncRNAs, miRNAs, and circRNAs that



**Figure 1. Morphologic and proliferative changes and immunophenotype upon senescence**

(A and E) Representative images of the fibroblast-like morphology of MSCs at P0 (A) and P4, P6, P8, P10, and P12 (E) are presented. Scale bars, 100  $\mu$ m. (B) CCK-8 assay of MSCs at P4, P6, P8, P10, and P12. (C) NCPD of MSCs from P4 to P12. (D) The continuous increase in cell size is reflected by the increasing forward-scatter signal in flow cytometry (FSC). (F) Representative cell cycle diagrams of MSCs during long-term culture at P4, P6, P8, P10, and P12. (G) Surface marker expression on MSCs at P4 and P12 analyzed using flow cytometry. Black lines represent isotype control. Data are presented as the means  $\pm$  SEM. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  compared with P4.  $n = 9$  MSCs per passage.

were differentially expressed (DE) in P12 compared with P4 (fold change  $|\log_2 [P12/P4]| \geq 1$ , Q value  $[P12/P4] < 0.001$ ), which have the same express trends in P6, and were abundantly expressed (mRNAs and circRNAs, FPKM  $\geq 5$ ; lncRNA and miRNA, FPKM  $\geq 2$ ) in MSCs from three donors were used for the subsequent analyses. A total of 792 RNAs were collected, among which there were 439 mRNAs (204 were upregulated and 235 were downregulated), 65 lncRNAs (48 were upregulated and 17 were downregulated), 229 circRNAs (202 were upregulated and 27 were downregulated), and 59 miRNAs (24 were upregulated and 35 were downregulated). The

DE RNAs are depicted using a clustergram (Figure 4A–4D). The top 5 mRNAs, lncRNAs, miRNAs, and circRNAs that were upregulated or downregulated with the largest fold changes are shown in Tables 2, 3, 4, and 5, respectively.

#### mRNA GO, KEGG, and GSEA analyses

We performed gene ontology (GO) analysis on the identified DE mRNAs. The top 20 GO terms related to biological processes, cellular components, and molecular functions are shown in Figures 4E–4G. The top 10 GO terms related to biological processes and DE mRNAs

**Table 1. Quantitative profiles of surface marker expression of MSCs at P4, P6, P8, P10, and P12 (n = 9, means ± SD)**

Marker	P4	P6	P8	P10	P12
CD105	94.05 ± 4.75	89.91 ± 11.13	68.27 ± 15.31	50.63 ± 16.25	47.38 ± 19.07
CD90	98.19 ± 1.27	97.67 ± 1.95	95.67 ± 2.02	92.53 ± 4.27	92.78 ± 4.71
CD73	97.48 ± 1.95	97.12 ± 2.95	93.17 ± 8.17	91.09 ± 3.17	89.76 ± 8.18
CD14	0.32 ± 0.36	0.31 ± 0.31	0.07 ± 0.12	0.18 ± 0.25	0.10 ± 0.15
CD34	0.01 ± 0.02	0.15 ± 0.22	0.04 ± 0.10	0.11 ± 0.16	0.05 ± 0.13
CD45	0.70 ± 0.64	0.32 ± 0.39	0.11 ± 0.16	0.23 ± 0.31	0.89 ± 0.51
HLA-DR	3.38 ± 1.55	4.49 ± 7.29	4.54 ± 5.06	4.89 ± 4.59	3.62 ± 7.85

associated with these terms are shown in Table 6. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of the DE mRNAs determined that 32 pathways were significantly altered in MSCs during *in vitro* aging ( $p < 0.05$ ). The top 20 enriched pathways are shown in Figure 4H. The top 10 pathways and DE mRNAs associated with these pathways are shown in Table 7. The top pathways included systemic lupus erythematosus, complement and coagulation cascades, Wnt signaling pathway, pathways in cancer, and Hedgehog signaling pathway, which are involved in immunity, signal transduction, proliferation, and differentiation. Gene set enrichment analysis (GSEA) identified 62 terms in MSCs of P12 compared with P4 (NOM  $p$  value  $< 0.05$ ). Some important terms like DNA replication, Notch signaling pathway, T cell receptor signaling pathway, Wnt signaling pathway, etc. were illustrated in Figure S1. Specifically, we focused on the terms and DE mRNAs identified in the GO biological process analysis of DE mRNAs related to proliferation, differentiation, or the immune response and selected these DE mRNAs as the gene set for analysis. The top 10 terms with the largest significant differences are listed in Tables S2–S4.

#### PPI and co-expression network analyses

Altogether, 127 nodes (56 upregulated and 71 downregulated genes) and 311 interaction pairs were identified in the PPI network of the DE mRNAs (Figure 5A). The nodes with high topological scores were noted to possibly play important roles during *in vitro* aging of MSCs. In this study, the hub nodes matrix metalloproteinase 9 (MMP9), G1/S-specific Cyclin D1 (CCND1), FGF2, C-X-C motif chemokine ligand 8 (CXCL8, also known as interleukin-8 [IL-8]), serpin family E member 1 (SERPINE1), and LEP that interacted with many other DE mRNAs were regarded as the key genes of the network. In addition, a co-expression network was constructed for DE lncRNAs and DE mRNAs (Figure 5B). Finally, we obtained 128 co-expression pairs (including 32 mRNAs and 6 lncRNAs) according to a Pearson correlation coefficient  $\geq 0.900$  cut-off value. LINC01013 had the highest number of targets, including 13 DE RNAs. LINC00607 and LOC102723409 were also demonstrated to be important RNAs. The top 20 co-expression pairs are shown in Table 8. Next, we analyzed the possible target genes of the DE lncRNAs and identified a total of 784 target genes. A Venn diagram analysis demonstrated that 8 mRNAs were found at the intersection of the 439 DE mRNAs and the 784 DE lncRNA *cis/trans*-target genes (Figure 5C). These 8 mRNAs and the lncRNAs are shown in Figure 5D,


which includes the LOC102723409-Rho GTPase activating protein 18 (ARHGAP18) *trans*-regulatory pair, a pair that was also identified in the co-expression analysis.

#### ceRNA networks

lncRNAs and circRNAs act as competing endogenous RNAs (ceRNAs) to exert their biological function; thus, we constructed ceRNA networks with lncRNAs and circRNAs as decoys, miRNAs as centers, and mRNAs as targets from all of the DE mRNAs, lncRNAs, and miRNAs to identify possible regulatory lncRNA/circRNA-miRNA-mRNA axes. A total of 21 miRNAs, 53 lncRNAs, and 130 mRNAs involving 204 regulatory relationships (Figures 6A–6C) and 16 miRNAs, 59 circRNAs, and 98 mRNAs involving 330 regulatory relationships (Figures 7A–7C) were obtained. We divided the ceRNA regulatory networks into two groups based on their gene expression patterns: down-up-down (Figures 6B and 7B) and up-down-up (Figures 6C and 7C). MIR99AHG, SMILR, LOC105747689, LINC01013, STXBP5-AS1, and LINC01503 were enriched in the ceRNA network. Next, we performed KEGG pathway analysis on these genes to identify pathway clusters. The related RNAs and the relationships between these pathways are shown in Figure 7D and include the autophagy and mitophagy signaling pathways, extracellular matrix (ECM)-receptor interactions, and PI3K-Akt signaling pathway. LOC102723409 and ITGA6-AS1 are the key lncRNAs involved in this network. INKA2-AS1, MIR99AHG, STXBP5-AS1, SMILR, LINC01503, and LOC105747689 are important lncRNAs involved in autophagy and the mitophagy pathways. Some circRNAs like circ\_0005773 and circ\_0058476 were identified in the circRNAs ceRNA network. The characteristics, like position, length, and parental genes, of the circRNAs involved in the prediction analysis were listed in Table S5.

#### Validation of the key RNAs expression

To verify the RNA-seq data and major findings from computational analysis, we performed quantitative real-time PCR for some key RNAs selected from the RNA networks. The expression levels of those RNAs were measured in 10 human BM-MSCs in a different passage. We designed specific divergent primers spanning the back-splice junction sites of circRNAs (Table S6). The qPCR results showed that the expression of miR-210-5p, miR-431-5p, ITGA6-AS1, INKA2-AS1, STXBP5-AS1, LOC102723409, LOC105747689, LINC



**Figure 2. In vitro differentiation and senescence detection of MSCs at P4, P6, P8, P10, and P12**


(A–C) Adipogenic differentiation (ORO staining) (A); osteogenic differentiation (ARS staining) (B); SA- $\beta$ -gal staining (C) of MSCs at P4, P6, P8, P10, and P12. Scale bars, 50  $\mu$ m in (A) and (C), 100  $\mu$ m in (B). (D) Quantification of ORO staining in (A). (E) Quantification of ARS staining in (B). (F) Percent of SA- $\beta$ -gal staining in (C). (G) Relative telomere length detection of MSCs in P4, P6, and P12. Data are presented as the means  $\pm$  SEM. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  compared with P4.  $n = 9$  MSCs per passage.

01013, circ\_0005773, circ\_0058476, circ\_0081571, circ\_0081562, COMP, STC1, ADAMTS1, INKA2 CDH6, STC2, and TINAGL1 were upregulated and that the expression of miR-1908-5p, miR-16-5p, miR-122-5p, miR-193a-3p, miR-199b-5p, miR-339-5p, MIR99-AHG, LINC01503, circ\_0078715, circ\_0078711, and SPON2 were downregulated (Figures 8A–8D). Other qPCR results were illustrated in Figure S2. To verify the back-splice junction sequences of circRNAs, we sent circ\_0005773 quantitative real-time PCR amplified products to Sanger sequencing, and the sequencing result confirmed the back-splice junction sites (Figure 8E). We confirmed that circ\_0005773 was resistant to RNase R, whereas its linear SERPINE2 mRNA level was significantly decreased after RNase R treatment (Figure 8F). Bioinformatic analyses indicated that circ\_0005773 could potentially bind to miR-17-5p. qPCR results showed the upregulated expression of circ\_0005773, downregulated expression of miR-17-5p, and upregulated expression of mRNA LIF, the possible targets of miR-17-5p, in MSCs of P12 compared with P4, consistent with the results of deep sequencing (Figures 8G–8I). The circ\_0005773/miR17-5p/LIF axis deserves further attention. All qPCR results were consistent with the RNA-seq results, confirming the reliability of the sequencing results, while more work still need to be done to validate the RNA network relationship.

## DISCUSSION

The present study identified a series of MSC aging-related mRNAs, miRNAs, lncRNAs, and circRNAs that are potential mediators of the changes in biological characteristics, such as decreased proliferation, differentiation, and immunosuppression abilities after long-term culture. Using a series of bioinformatics analyses, LOC1027234409, IT-GAS6-AS1, MIR99AHG, LINC01013, etc., and some circRNAs were identified based on our prediction. By constructing a ceRNA network with lncRNAs/circRNAs, miRNAs, and mRNAs, we identified the links between these RNA species. Further functional analyses suggested a potential mechanism through which these ceRNAs mediated MSC aging. This is the first systematic analysis of lncRNAs and circRNAs and their functional networks in human MSCs at early and late passages, which emphasize the important role of lncRNAs and circRNAs in the replicative senescence of BM-MSCs, although more research is necessary to confirm our findings.

Many studies have reported that MSCs undergo the typical Hayflick phenomenon of cellular senescence, characterized by decreased proliferation and changes in cell morphology, and exhibit an aberrant phenotype of irregular fattened geometry and enlarged size during long-term culture.<sup>13</sup> Consistent with this, we found that senescence




**Figure 3. Ability of MSCs at different passages to inhibit T cell and B cell proliferation**

(A) Flow cytometric analysis of CD4<sup>+</sup> T cell proliferation in the presence of MSCs at P4, P6, P8, P10, and P12. Nonactivated CD4<sup>+</sup> T cells were defined as the blank group. The proliferation rate of CD4<sup>+</sup> T cells was markedly elevated when the cells were stimulated by CD3/CD28. (B) Quantification of the CD4<sup>+</sup> T cell proliferation rate in (A). (C) Flow cytometric analysis of CD19<sup>+</sup> B cell proliferation in the presence of MSCs at P4, P6, P8, P10, and P12. Nonactivated CD19<sup>+</sup> B cells were defined as the blank group. The proliferation rate of CD19<sup>+</sup> B cells was markedly elevated upon stimulation with LPS. (D) Quantification of the CD19<sup>+</sup> B cell proliferation rate in (C). Data are presented as the means  $\pm$  SEM. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .  $n = 9$  MSCs per passage.

obviously occurred after P6–P8, which is compatible with expansion rates of  $10^6$ -fold to  $10^8$ -fold (ranging from 16 to 24 population doublings). The decreased CD105 was detected, while CD90 and CD73 were relatively stable after prolonged passaging, consistent with previous reports.<sup>15,23</sup> CD105, which is the same as Stro-1, has been considered to be more applicable to be used as phenotypic markers of MSCs multipotency.<sup>24</sup> Typical MSC markers such as CD90 and CD73 appear not enough or specific in indicating maintenance of “stemness,” and that multiparametric immunophenotyping, including CD105 or other stem cell markers, should be supplemented. In addition, decreased adipogenic differentiation abilities of MSCs during *in vitro* aging were observed in our studies, in accordance with the previous reports.<sup>10,13</sup> However, the propensity for osteogenic differentiation of MSCs during *in vitro* aging were still discordant. Wagner et al.<sup>10</sup> suggested that osteogenic differentiation increases at higher passages. Yu et al.<sup>25</sup> reported that the osteogenic differentiation potential increased up to P10 and decreased thereafter. Yang et al.<sup>13</sup> suggested that osteogenic differentiation abilities of MSCs during *in vitro* aging were decreased as a generation, consistent with our

studies. These conflicting results of the differentiation ability of MSCs during long-term culture demonstrated that further study is needed. Consistent with our results, De Witte et al.<sup>14</sup> reported that long-term expansion induced aging of human UC MSCs (hUC-MSCs), which exhibited reduced immunosuppressive properties from P4 to P12.

Moreover, recent studies found that changes in transcriptome and epigenetic regulation in hUC-MSCs occurred during long-term expansion.<sup>26–28</sup> mRNA expression profiles reflect the biological behaviors and functions of cells.<sup>14</sup> These changes in mRNA expression profiles are closely related to the functional changes during *in vitro* aging.<sup>29</sup> We identified 768 DE mRNAs between P12 and P4, with a consistent trend in P6. Among these, DE mRNAs, NEFM, SERPINB2, CD52, and MMP9 were the most significantly changed. In addition, GO analysis demonstrated enrichment of specific biological processes, such as ossification and cell differentiation. KEGG and GSEA identified some environmental information processing signaling pathways, including ECM-receptor interaction, Wnt signaling pathway, Hedgehog signaling pathway, PPAR signaling



**Figure 4. Heatmaps of DE RNAs and functional enrichment analysis of DE mRNAs**

(A–D) Heatmaps of DE mRNAs (A), DE circRNAs (B), DE lncRNAs (C), and DE miRNAs (D) between the P4 and P12 groups and with a similar trend in P6 (n = 3 per passage). (E–G) DE mRNAs were clustered by GO analysis, and the top 20 terms of molecular function (E), biological process (F), and cellular component (G) are shown, respectively. (H) DE mRNAs were clustered by KEGG analysis, and the top 20 pathways are shown.

pathway, and Jak-STAT signaling pathway. Part of these findings and analysis were confirmed in Figure S2. These signal transduction pathways play important roles in SA functional changes.<sup>30,31</sup> Notably, the SLE and AGE-RAGE signaling pathways in diabetic complications and insulin resistance were also among the pathways identified as having the most significant difference by KEGG analysis. These results are consistent with those of a previous study and emphasize the importance of MSC senescence in the pathogenesis and clinical treatment of autoimmune and metabolic diseases.

In the interactions between proteins encoded by DE, mRNAs, MMP9, CXCL8, SERPINE1, and LEP were identified as the key genes that interact with many other DE mRNAs in this network. MMP9 is involved in the breakdown of extracellular matrix in normal physiological processes and integrates multiple immunoregulatory pathways that determine the high suppressive activity of hMSCs.<sup>32</sup> CXCL8 was demonstrated to play an important role in neutrophil activation and

migration and could also recruit T leukomonocytes, monocytes, etc.<sup>33</sup> CXCL8 mediates CD4<sup>+</sup> T cell migration regulated by MSCs through autophagy.<sup>34</sup> SERPINE1 has been reported to be involved in cellular and replicative senescence<sup>35</sup> and in the regulation of odontoblast differentiation of periodontal ligament stem cells.<sup>36</sup> LEP can maintain mitochondrial integrity and prolong the survival of hMSCs.<sup>37</sup> The MMP family members and some kinds of chemokines as the SA secretory phenotype (SASP) components have been reported to be consistently up-regulated in senescent cells,<sup>38</sup> consistent with our sequencing results. The expression of these molecules was partly validated in Figure S2. Therefore, these proteins may be used as indicators for the characterization of MSCs after long-term culturing. However, whether these proteins can be used as markers in clinical detection remains to be further studied.

mRNA expression profiles are under the control of a series of epigenetic regulators, of which ncRNAs, such as lncRNAs, miRNAs, and circRNAs, are important components. Numerous

studies have confirmed that lncRNAs and miRNAs regulate the aging of MSCs,<sup>21,22</sup> and the function of circRNAs in MSC fate decisions has emerged.<sup>19,39</sup> However, the circRNAs involved in the aging of MSCs remain unknown, and a comprehensive analysis of lncRNAs involved in MSC aging is also lacking. In this study, we first determined the ncRNA expression profiles involved in MSC long-term culture and found that 65 lncRNAs, 59 miRNAs, and 229 circRNAs were DE in MSCs at P12 compared with P4. These DE lncRNAs/circRNAs may contribute to the differential expression of mRNAs and thus may be involved in aging-related changes in MSCs. What's more, the interacting ncRNA cascades can serve as a novel and potential therapeutic target for MSCs application and molecular therapy. The expression of some key ncRNAs involved in the predicted analysis were validated in Figure 8.

lncRNAs can function in *cis*, at the site of transcription, or in *trans* and as such participate in multiple networks regulating gene

**Table 2. Characteristics of mRNAs with the largest fold changes (P12 versus P4)**

Gene ID	Gene symbol	Fold change (log <sub>2</sub> [P12/P4])	Regulation
4741	NEFM	5.439747	UP
5055	SERPIN2	5.239469	UP
3952	LEP	4.578009	UP
11075	STMN2	4.034502	UP
730755	KRTAP2-3	3.945871	UP
1043	CD52	-9.50693	DOWN
4318	MMP9	-8.25542	DOWN
165	AEBP1	-4.1185	DOWN
54	ACP5	-3.78729	DOWN
81035	COLEC12	-3.76893	DOWN

expression and function.<sup>40</sup> We identified three pairs of genes that interact through *cis*-regulation and five pairs that interact through *trans*-regulation, which may be involved in the regulation of MSC aging. In addition, the ARHGAP18-LOC102723409 pair was identified in the co-expression and target analysis, and the ARHGAP29-LINC01013 pair was identified in the co-expression analysis. The ARHGAP genes encode a family of at least 32 members of the RhoGAP protein family with variable functions,<sup>41</sup> including maintenance and control of the actin cytoskeleton, angiogenesis, cell proliferation, differentiation, and survival.<sup>42</sup> However, their functions in MSCs, especially in the aging process, have not yet been determined, and in our study, the increased levels of ARHGAP29 and ARHGAP18 during expansion and the relationship with lncRNAs need more attention in the future.

One of the most critical roles of lncRNAs and circRNAs is their ability to act as ceRNAs for miRNAs and relieve mRNAs from miRNA targeting.<sup>43</sup> Successful applications of molecular network analysis have been reported in multiple diseases and drug development.<sup>44</sup> The cross-talk between ceRNAs through shared miRNAs represents a novel layer of gene regulation that plays an important role in the aging of MSCs.<sup>45</sup> However, the specific lncRNAs/circRNAs involved in the immunoreg-

ulatory, proliferative, and differentiation capacities of MSCs during aging require further research. Therefore, a core ceRNA network was constructed between DE mRNAs, lncRNAs/circRNAs, and miRNAs based on DE miRNAs targeting interactions, which allowed us to identify several key lncRNAs and circRNAs. The synergically expressed mRNAs and lncRNAs/circRNAs but divergently expressed miRNAs represented the core ceRNAs.<sup>44</sup> Therefore, we analyzed the up-down-up and down-up-down relationships of DE lncRNAs/circRNAs, miRNAs, and mRNAs for ceRNA network construction. Combining the ceRNA and KEGG analyses of these genes, we identified several key lncRNAs, including LINC01013, LOC102723409, ITGA6-AS1, INKA2-AS1, MIR99AHG, LINC01503, SMLR, STXBP5-AS1, and LOC105747689, which were not explored in BM-MSCs in previous studies.

Among them, LINC01013, INKA2-AS1, ITGA6-AS1, LOC105747689, and STXBP5-AS1 all showed intimate interactions with miR-339-5p and miR-1908-5p, both of which have been reported to regulate the osteogenic differentiation of BM-MSCs.<sup>46,47</sup> Besides, LINC01013 had the highest number of co-expression targets and the top correlation coefficient. It has been reported to negatively regulate the chondrogenic differentiation potential of stem cells.<sup>48</sup> INKA2-AS1 was also predicted to *cis*-target INKA2, which is a novel, direct downstream target of p53 that potentially decreases cell growth by inhibiting the PAK4/ $\beta$ -catenin pathway<sup>49</sup> and is involved in mechanisms regulating the actin cytoskeleton and actin-driven processes.<sup>50</sup> ITGA6-AS1/PDK1 is another *cis*-target gene pair. ITGA6-AS1, also named AC078883.3, is enriched in ion binding, transport, cell-cell signaling, and plasma membrane parts and is mainly related to the calcium signaling pathway and the mitogen-activated protein kinase signaling pathway.<sup>51</sup> LOC105747689, also named AK130181, which is highly expressed in CD4<sup>+</sup> T lymphocytes, suppresses nuclear factor- $\kappa$ B (NF- $\kappa$ B) activity.<sup>52</sup> STXBP5-AS1 was reported to inhibit cell proliferation<sup>53</sup> and also coexpressed with PRUNE2 in our co-expression analysis. To our knowledge, the role of these lncRNAs in MSC aging has not yet been reported. Future research could focus on these lncRNAs to identify their role in MSC functional changes during aging.

**Table 3. Characteristics of lncRNAs with the largest fold changes (P12 versus P4)**

Gene ID	Gene symbol	Fold change (log <sub>2</sub> [P12/P4])	Chromosome	Strand	Start	End	Regulation
100750247	HIF1A-AS2	4.959349	NC_000014.9	-	61747039	61749089	UP
106480738	OSTN-AS1	4.729266	NC_000003.12	-	191212868	191235780	UP
109729169	LINC02154	4.043334	NC_000023.11	+	13246302	13329958	UP
152742	LINC01085	2.826299	NC_000004.12	+	14111968	14143592	UP
100506343	INKA2-AS1	2.790145	NC_000001.11	+	111738607	111753572	UP
107984611	LOC107984611	-5.35235	NC_000013.11	-	42767224	42819890	DOWN
388011	LINC01550	-5.35235	NC_000014.9	+	97925610	98542334	DOWN
102724678	LINC01423	-5.28412	NC_000021.9	+	38323635	38346076	DOWN
105377043	LOC105377043	-5.18423	NC_000003.12	+	40717410	40878958	DOWN
100192378	ZFHX4-AS1	-1.86988	NC_000008.11	+	76491200	76683672	DOWN



**Table 4. Characteristics of miRNAs with the largest fold changes (P12 versus P4)**

Gene ID	Fold change (log <sub>2</sub> [P12/P4])	Chromosome	Strand	Start	End	Regulation
hsa-miR-302b-3p	3.39128	NC_000004.12	-	112648489	112648511	UP
hsa-miR-302a-3p	3.32416	NC_000004.12	-	112648186	112648208	UP
hsa-miR-302d-3p	2.5962	NC_000004.12	-	112648006	112648028	UP
hsa-miR-483-5p	2.03057	NC_000011.10	-	2134181	2134202	UP
hsa-miR-451a	1.97568	NC_000017.11	-	28861403	28861424	UP
hsa-miR-122-5p	-1.47252	NC_000018.10	+	58451088	58451109	DOWN
hsa-miR-3613-5p	-1.50052	NC_000013.11	-	49996465	49996486	DOWN
hsa-miR-199b-5p	-2.84583	NC_000009.12	-	128244783	128244805	DOWN
hsa-miR-3529-3p	-6.02915	NC_000015.10	-	88611856	88611879	DOWN
hsa-miR-206	-6.04024	NC_000006.12	+	52144401	52144422	DOWN

Our *trans*-regulation results indicated the MIR99AHG and its target gene ZNF608, and the ceRNAs network reminded that the miR-134-5p may be a regulator involved in the MIR99AHG-ZNF608 pair. MIR99AHG has been reported to have a role in cell proliferation and differentiation.<sup>54</sup> Moreover, MIR99AHG-ZNF608 was found to be involved in the autophagy and mitophagy signaling pathways in the KEGG analysis. LOC102723409 connected with and regulated several important pathways based on the KEGG analysis, which may be mediated through sponging miR-16-5p, miR-122-5p, and miR-17-5p based on the ceRNA prediction or through ARHGAP18 etc. co-expression mRNAs. LINC01503 could promote proliferation by acting as a ceRNA,<sup>55</sup> and miR-210, a pro-survival and anti-apoptotic factor,<sup>56</sup> miR-432-5p, and miR-1228-5p may deserve further attention to explore the role and mechanism of LINC01503 in MSC aging.

In addition to lncRNAs, circRNAs can also act as ceRNAs to sponge miRNAs and regulate pathological and physiological processes, including aging-related processes.<sup>57,58</sup> circRNAs are a new class of noncoding single-stranded RNAs that differ from linear lncRNAs in that they form covalently closed loop structures without free 3' poly(A) tails or 5' caps. Due to the stability of circRNAs, their potential adsorption of miRNAs is stronger than that of lncRNAs and

mRNAs.<sup>59</sup> Our RNA-seq analysis showed that MSC aging was accompanied by the upregulation of many circRNAs (Figure 4B). Whether these circRNAs function as miRNA sponges to counteract miRNA-mediated repression of mRNAs during MSC aging deserves our attention. circRNAs, generated from genes of THBS1, THBS2, SERPINE1, SERPINE2, LOXL2, LDHA, CCND1, etc. were predicted in the ceRNAs network. Some of circRNAs' function generated from these genes have been investigated. circSERPINE2, which is formed by the circularization of exons 2–4 of Serpine2 gene, alleviated IL-1-β-induced chondrocytes apoptosis and extracellular matrix degradation.<sup>60,61</sup> circTHBS1 and circ-CCND1 (hsa\_circ\_0023303) promote cell proliferation.<sup>62–64</sup> Circ\_0005773 was existed and highly expressed in MSCs. The expression of the predicted circ\_0005773/miR-17-5p/LIF axis was validated (Figure 8). However, the function of many other circRNAs has not been demonstrated yet, not even in the MSC aging.

In conclusion, MSCs expansion is accompanied with a series of biological changes and transcriptome drift, which deserve more concern, especially in MSCs manufacturing protocol. The key RNAs reported here may allow us not only to interrogate for biomarkers and to evaluate relative levels of desired genes to refine parameters for maximum MSCs expansion without compromising therapeutic efficacy but also

**Table 5. Characteristics of circRNAs with the largest fold changes (P12 versus P4)**

Gene ID	Fold change (log <sub>2</sub> [P12/P4])	Chromosome	Strand	Start	End	Gene symbol	Regulation
hsa_circ_0081567	2.473584	NC_000007.14	+	101130421	101130654	SERPINE1	UP
hsa_circ_0081564	2.384603	NC_000007.14	+	101128393	101128664	SERPINE1	UP
hsa_circ_0073686	2.371695	NC_000005.10	-	122070494	122075541	LOX	UP
hsa_circ_0081565	2.364576	NC_000007.14	+	101128393	101132069	SERPINE1	UP
hsa_circ_0081574	2.358868	NC_000007.14	+	101135494	101137084	SERPINE1	UP
hsa_circ_0135618	-2.3529	NC_000008.11	+	120147806	120168247	COL14A1	DOWN
hsa_circ_0116771	-2.35738	NC_000022.11	+	45541229	45542283	FBLN1	DOWN
hsa_circ_0063743	-2.36496	NC_000022.11	+	45525543	45528009	FBLN1	DOWN
hsa_circ_0063750	-2.45822	NC_000022.11	+	45541229	45543526	FBLN1	DOWN
hsa_circ_0063758	-2.69773	NC_000022.11	+	45562912	45563362	FBLN1	DOWN

**Table 6. Top 10 terms with the largest significant differences in the GO biological process analysis of DE mRNAs**

Term	Count	Rich ratio	p value	Candidate gene
Extracellular matrix organization	25	0.090909	2.24E-11	OLFML2B, NDNF, MMP11, OLFML2A, COL16A1, RECK, ADAM19, ITGA10, TNC, FBLN1, FGF2, MMP9, SERPINE1, COL5A3, EVI2A, TGFBI, THBS1, MFAP2, COMP, ERO1A, TNFRSF11B, COL14A1, KAZALD1, ABI3BP, COL4A1
Ossification	15	0.12605	2.79E-09	TMEM119, LRRC17, IFITM1, MMP9, STC1, ACP5, MMP16, TWIST1, CLEC3B, PTN, COMP, RUNX2, KAZALD1, MGP, IGF2
Cell adhesion	38	0.048906	1.46E-08	COL16A1, TINAGL1, S1PR1, RGMB, NRP2, PVR, ITGA10, TNC, EGFL7, JUP, THBS2, LOXL2, SCN1B, COL5A3, TGFBI, THBS1, MTSS1, PCDHGC3, CDH6, SPON2, BCAM, CXCL12, RND3, PERP, PCDHGB7, THBS3, COMP, CGREF1, PCDHGA10, COL14A1, CADM1, NRCAM, WISP2, SELENOP, MFAP4, GPNMB, EPHA2, PTPRU
Collagen fibril organization	11	0.161765	2.64E-08	MMP11, GREM1, PLOD2, LOXL2, COL5A3, EVI2A, LOX, COMP, COL14A1, LOXL4, P4HA1
Nucleosome assembly	15	0.088757	3.21E-07	SMYD3, HIST1H4F, HIST1H1B, HIST1H4E, HIST1H2BI, HIST2H3D, HIST1H2BO, HIST1H4J, HIST1H4L, HIST1H4K, HIST1H4A, HIST1H3I, HIST1H3H, HIST1H3A, HIST1H2BN
Angiogenesis	21	0.058496	1.73E-06	LEP, NDNF, GREM1, ANGPTL4, S1PR1, NRP2, SLC38A1, EPGN, CXCL8, EPHB2, EGFL7, ADGRA2, SERPINE1, JAG1, TGFBI, FZD8, CAV1, CCBE1, NRCAM, EPHA2, COL4A1
Cellular response to hypoxia	13	0.089655	1.75E-06	NDNF, MGARP, ANKRD1, STC1, TWIST1, FMN2, STC2, EDN1, PTN, NOP53, ZFP36L1, BNIP3, ERO1A
Skeletal system development	14	0.075676	5.25E-06	SH3PXD2B, FAM20C, NPR3, SOX4, PAPSS2, MMP9, ANKH, EDN1, AEBP1, COMP, RUNX2, TNFRSF11B, EPHA2, IGF2
Negative regulation of blood coagulation	5	0.294118	8.40E-06	APOE, TFPI, SERPINE1, EDN1, SERPINE2
Amino acid transport	8	0.131148	1.09E-05	SLC7A11, SLC38A1, SLC1A1, SLC7A14, SLC7A8, SLC38A5, PDPN, SLC43A1

to identify strategies to rejuvenate senescent MSCs to broaden the range of therapeutic applications of MSCs.

## MATERIALS AND METHODS

### Human BM-MSC isolation and passage

This study was approved by the Ethics Committee of Eighth Affiliated Hospital, Sun Yat-sen University (Shenzhen, People's Republic of China). All donors in our study were informed of the possible risks and the study objectives and signed informed consent forms. 20 healthy donors (10 males, 10 females) between the ages of 20 and 30 years who had no history of any significant illness were selected for the study. BM was extracted from the posterior superior iliac spine under sterile conditions, and MSCs were isolated and purified according to a previously reported method.<sup>7</sup> MSCs were always passaged at the same density of approximately 70% confluence and cultured with Dulbecco's modified Eagle's medium (DMEM; GIBCO) containing 10% fetal bovine serum (FBS; GIBCO) and sup-

plemented with growth factors (FGF) at 37°C in a 5% CO<sub>2</sub> atmosphere.

### Flow cytometry

MSCs were detached and incubated for 30 min at room temperature with the following specific antibodies: PE mouse anti-human CD90 (immunoglobulin G [IgG], k, clone: 5E10), FITC mouse anti-human CD73 (IgG1, k, clone: MAR4), PE rat anti-human CD14 (IgG2b, k, clone: G44-26), PE mouse anti-human CD105 (IgG1, k, clone: 266), APC rat anti-human CD45 (IgG2b, k, clone: 30-F11), PE mouse anti-human CD34 (IgG1, k, clone: 563) and PE mouse anti-human HLA-DR (IgG2a, k, clone: G46-6; all from BD Biosciences, San Jose, CA, <http://wwwbdbiosciences.com>). Finally, the cells were assayed using a BD Influx Cell Sorter (BD Biosciences). For the cell cycle analysis, MSCs were trypsinized and fixed with 80% cold alcohol at 4°C for 12 h. After centrifugation, MSCs were resuspended in 50 µL of RNase and 450 µL of propidium iodide (PI; Sigma-Aldrich)

**Table 7. Top 10 biological pathways with the largest significant differences in the KEGG pathway analysis of DE mRNAs**

Pathway	Count	Rich ratio	p value	Gene
Systemic lupus erythematosus	21	0.094595	2.77E-10	HIST1H4F, HIST1H4E, HIST1H2BI, HIST2H3D, HIST2H2AB, HIST1H2AH, HIST1H2BO, HIST1H4J, HIST1H4L, C1S, HIST1H4K, HIST1H4A, HIST2H2AC, HIST1H2AB, C1R, HIST1H3I, 105369230, HIST1H3H, HIST1H2AM, HIST1H3A, HIST1H2BN
Alcoholism	20	0.096154	5.59E-10	BDNF, HIST1H4F, HIST1H4E, HIST1H2BI, HIST2H3D, HIST2H2AB, HIST1H2AH, HIST1H2BO, HIST1H4J, HIST1H4L, HIST1H4K, SHC2, HIST1H4A, HIST2H2AC, HIST1H2AB, HIST1H3I, HIST1H3H, HIST1H2AM, HIST1H3A, HIST1H2BN
Malaria	7	0.102941	1.67E-04	CXCL8, THBS2, THBS1, GYPC, THBS3, COMP, SDC1
Complement and coagulation cascades	9	0.076271	2.07E-04	CLU, TFPI, SERPINE1, C1S, C1R, CD55, CFI, SERPINB2, CFB
ECM-receptor interaction	8	0.063492	0.001548	ITGA10, TNC, THBS2, THBS1, THBS3, COMP, SDC1, COL4A1
Wnt signaling pathway	10	0.052632	0.001745	GREM1, PLCB4, CCND1, FZD8, DKK1, DVL2, PORCN, SERPINE1, CCND2, SFRP4
AGE-RAGE signaling pathway in diabetic complications	8	0.061069	0.00198	STAT5A, PLCB4, CXCL8, CCND1, SERPINE1, EDN1, STAT1, COL4A1
Pathways in cancer	24	0.032742	0.002047	NOTCH3, DAPK2, STAT5A, SULF2, PLCB4, CXCL8, JUP, FGF2, MMP9, FGF5, CCND1, GLI3, JAG1, FZD8, GSTM4, STAT1, CXCL12, DVL2, SLC2A1, TXNRD1, ABI3BP, IGF2, COL4A1, CCND2
Protein digestion and absorption	7	0.066667	0.002287	COL16A1, SLC1A1, COL5A3, SLC7A8, COL14A1, VWCE, COL4A1
Bladder cancer	5	0.089286	0.002755	DAPK2, CXCL8, MMP9, CCND1, THBS1

staining solution, and the phases of the cell cycle in each sample after 30 min of incubation were analyzed by flow cytometry.

### MSC propagation

Two methods were conducted to detect the proliferative capability of MSCs during *in vitro* aging. Cells collected at the end of each passage were counted using a trypan blue exclusion method. The NCPD<sup>13</sup> was then calculated based on the following equation:  $NCPD = 3.33 \times \log(N_t/N_i)$ .  $N_t$  and  $N_i$  are the cell numbers at a specific time point  $t$  (day 14) and at initial seeding (day 0), respectively. In addition, MSCs at P4, P6, P8, P10, and P12 were seeded in 96-well microplates and subjected to different treatments for the indicated times. A cell counting kit-8 (CCK-8) assay (Dojindo Molecular Technologies, Rockville, MD, <http://www.dojindo.com>) was used to assess the cell proliferation ability at days 0, 1, 2, 3, 4, and 5 according to the manufacturer's protocol.


### MSC adipogenic and osteogenic differentiation

MSCs were seeded at a concentration of  $0.5 \times 10^4$  cells per well in 12-well plates, and osteogenic differentiation was induced by the addition of DMEM supplemented with 10% FBS, 100 IU/mL penicillin, 100 IU/mL streptomycin, 0.1 mM dexamethasone, 10 mM

$\beta$ -glycerol phosphate, and 50 mM ascorbic acid (Sigma-Aldrich, St. Louis, MO, <https://www.sigmaaldrich.com>). The medium was replaced every 3 days for 21 days. Differentiated cells were stained with ARS to detect the *de novo* formation of bone matrix. For adipogenic induction, MSCs were induced in adipogenic medium consisting of high-glucose DMEM supplemented with 10% FBS, 1 mM dexamethasone (Sigma-Aldrich), 10 mg/mL insulin (Sigma-Aldrich), 0.5 mM 3-isobutyl-1-methylxanthine (Sigma-Aldrich), and 0.2 mM indomethacin (Sigma-Aldrich). The cells were stained with ORO on day 21.

### SA- $\beta$ -gal staining and relative telomere length detection

The expression of pH-dependent SA- $\beta$ -gal activity was analyzed in MSCs at different passages using the SA- $\beta$ -gal staining kit (Cell Signaling Technology, #9860) according to previous report.<sup>23</sup> We used quantitative PCR proposed by Cawthon in 2002 to measure the telomere length.<sup>65</sup> Genomic DNAs of MSCs of P4, P6 and P12 were extracted. The ratio of telomere (T) and single copy gene (S), named T/S ratio =  $[2^{Ct(\text{Telomeres})}/2^{Ct(S)}]^{-1} = 2^{-\Delta Ct}$ , was determined using the Telomere length detection kit (Ji Pu, #GP1501). Since the T/S ratio is proportional to the telomere length, the relative length of the telomere can be obtained by the T/S ratio.



**Figure 5. Interaction and co-expression/co-localization network analyses**

(A) Interactions between DE mRNAs. (B) Co-expression network of DE lncRNAs and DE mRNAs. (C) Venn diagram showing DE mRNAs and *cis/trans*-target genes of DE lncRNAs. Circles indicate coding genes, and rhombuses indicate lncRNAs. Red nodes indicate upregulated genes, and blue nodes indicate downregulated genes (P12/P4). The edges indicate the interaction between two nodes. Black arrows indicate the key lncRNAs.

### CD4<sup>+</sup> T cell and CD19<sup>+</sup> B cell proliferation assay

PBMCs were collected and purified from the peripheral blood of 6 healthy donors (3 males, 3 females) using Ficoll-Hypaque gradient centrifugation (GE Healthcare Life Sciences, Marlborough, MA, <http://www.gelifesciences.com>). CD4<sup>+</sup> T cells and CD19<sup>+</sup> B cells were purified with CD4 and CD19 immunomagnetic bead antibodies, respectively, incubated with 5 mM carboxyfluorescein succinimidyl ester (CFSE, Thermo Fisher Scientific, Waltham, MA, USA, <http://www.thermofisher.com>) for 15 min, washed with PBS containing 10% FBS, and then added to the coculture system with 2 mL medium at a ratio of 1:5 or 1:1 (MSCs [ $0.5 \times 10^5$  cells]:CD4<sup>+</sup> T [ $2.5 \times 10^5$  cells] or CD19<sup>+</sup> B cells [ $0.5 \times 10^5$  cells]). The cells were cocultured in RPMI-1640 medium containing purified anti-CD3 (0.2 mg/mL, BD Biosciences) and anti-CD28 (1 mg/mL, BD Biosciences) antibodies to stimulate the T cells and LPS (2.5  $\mu$ g/mL, Sigma-Aldrich, L2630) to stimulate the B cells to proliferate for 5 days. CD4<sup>+</sup> T cell and CD19<sup>+</sup> B cell proliferation was measured by fluorescence-activated cell sorting.

### Library construction and high-throughput sequencing

A total of nine samples consisted of three MSCs at P4, P6, and P12, respectively, were separately treated with TRIzol (TAKARA), and then two libraries were constructed: lncRNA library and miRNA library. In the lncRNA-seq, after removing rRNA using Ribo-Zero Magnetic Kit (Epicenter), the retrieved RNA was fragmented by adding First Strand Master Mix (Invitrogen) using random primers reverse transcription followed by a second-strand cDNA

synthesis. Then the cDNA fragments were subjected end-repair and then were 3' adenylated following by adaptor ligation and enrichment with several rounds of PCR amplification. The library products were evaluated using the Agilent 2100 bioanalyzer (Thermo Fisher Scientific, USA) and then sequenced on Illumina HiSeq X-ten platform with paired-end 100 bp at BGI. Tech (BGI-Shenzhen, China). The sequencing data were filtered with SOAPnuke (v1.5.2) in FASTQ format. The total number of clean reads is about 120M for one sample. The clean reads were mapped to GCF\_000001405.38\_GRCh38.p12 using HISAT2. Particularly, we analyzed circRNAs, classical genes, and lncRNAs, separately. Database of circbase (<http://circrna.org/>) was used to identify circRNAs by BLAST. The expression level of gene was calculated by RSEM (v.1.2.12). The following all analyses including heatmap, GO, KEGG, and GSEA et al. of annotated DE gene were conducted with the online bioinformatic platform Dr. Tom (<https://biosys.bgi.com/>) provided by BGI.

In the miRNA sequencing, total RNA was purified by electrophoretic separation on a 15% urea denaturing polyacrylamide gel electrophoresis (PAGE) gel and small RNA regions corresponding to the 18–30 nt bands in the marker lane (14–33 single-stranded RNA [ssRNA] Ladder Marker, TAKARA) were excised and recovered. The purified RNAs were then ligated with 3' RNA adaptor and followed by 5' adaptor ligation. The adaptor-ligated small RNAs were subsequently transcribed into cDNA and several rounds of PCR amplification were performed. The PCR products

**Table 8. Top 10 co-expression pairs of DE mRNAs and lncRNAs**

Source ID	Gene symbol	Target ID	Gene symbol	Correlation coefficient
7057	THBS1	100507254	LINC01013	0.972
1901	S1PR1	100507254	LINC01013	0.963
9411	ARHGAP29	100507254	LINC01013	0.952
100507254	LINC01013	51232	CRIM1	0.949
114902	C1QTNF5	100507254	LINC01013	0.947
102723761	LINC02773	7123	CLEC3B	0.946
729178	STXBP5-AS1	158471	PRUNE2	0.943
11217	AKAP2	100507254	LINC01013	0.941
79674	VEPH1	100507254	LINC01013	0.939
79642	ARSJ	646324	LINC00607	0.939
25825	BACE2	100507254	LINC01013	0.938
5166	PDK4	102723761	LINC02773	0.938
5552	SRGN	646324	LINC00607	0.935
5176	SERPINF1	102723761	LINC02773	0.935
102723409	LOC102723409	93663	ARHGAP18	0.933
100507254	LINC01013	25925	ZNF521	0.933
7436	VLDLR	102723761	LINC02773	0.933
9411	ARHGAP29	646324	LINC00607	0.930
5552	SRGN	102723409	LOC102723409	0.928
102723409	LOC102723409	9411	ARHGAP29	0.924

were selected by PAGE with target fragments 100–120 bp and purified by QIAquick Gel Extraction Kit (QIAGEN, CA). After being evaluated using the Agilent 2100 bioanalyzer (Thermo Fisher Scientific, USA), the purified library products were then sequenced with a 50 bp single-end run on a BGISEQ 500 platform at BGI Tech (BGI-Shenzhen, China). After sequencing, the raw reads were filtered by FASTQC to get clean reads. The total number of clean reads is about 20M for one sample. After filtering, the clean reads were mapped to the reference genome (GCF\_000001405.38\_GRCh38.p12) and other small RNA (sRNA) database including miRbase, small interfering RNA (siRNA), Piwi-interacting RNA (piRNA), and small nucleolar RNA (snoRNA) with Bowtie2. The miRNA expression was calculated by RPM (reads per million) values. Differential expression analysis was performed using the DEGseq according to the criteria of  $|\log_2(\text{fold change})| \geq 1$  and  $Q\text{-value} < 0.001$ . TargetScan, RNAhybrid, miRanda were used to predict targets gene of selected miRNA on the online tool Dr. Tom software (BGI-Shenzhen, China).

#### Protein-protein interaction network analysis

Dr. Tom (<http://biosys.bgi.com>) was used to evaluate the protein-protein interaction (PPI) network of the DE coding genes. The PPI score was set as 0.9 (highest confidence). All the nodes in the PPI network were DE mRNAs. The network was visualized using Cytoscape version 3.6.1 (<http://www.cytoscape.org/>). The topological property of degree centrality was used to analyze the node score in the network.

#### Co-expression network analysis


The Pearson's correlation coefficient of each DE lncRNA and mRNA was calculated, and the correlation test was performed on Dr. Tom (<http://biosys.bgi.com>) to identify lncRNA-mRNA pairs. The mRNA-lncRNA pairs with Pearson correlation  $> 0.900$  and  $p\text{ value} < 0.01$  were collected for co-expression network construction.

#### Analysis of lncRNAs targeting mRNAs

To identify cis-regulatory interactions, we investigated lncRNAs that act on neighboring target genes. We searched for coding genes 20 k upstream and downstream of each lncRNA. The binding energy was used to identify *trans*-regulatory targets of lncRNAs. Binding energy  $\leq -100$  was as the criterion of *trans*-regulatory interactions.

#### ceRNA network analysis

Along with the identified DE mRNAs, lncRNAs, and miRNAs, we constructed a ceRNA network. First, we used starBase (<http://starbase.sysu.edu.cn/>)<sup>66</sup> and Dr. Tom (<http://biosys.bgi.com>) to predict the DE miRNA-targeted lncRNAs with scores  $> 0.75$ , which were then intersected with the DE lncRNAs. Next, we used TargetScan (<http://www.targetscan.org/>) and Dr. Tom to identify miRNA-targeted mRNAs, which were then intersected with the DE mRNAs. Finally, the interaction network was constructed and visualized using Cytoscape software based on the screening of lncRNA-miRNA-mRNA pairs.



**Figure 6.** ceRNA network of lncRNA-miRNA-mRNA interactions

(A) Venn diagram showing the intersection of DE mRNAs and target mRNAs of DE miRNAs and the intersection of DE lncRNAs and target lncRNAs of DE miRNAs. (B and C) ceRNA regulatory network of lncRNA-miRNA-mRNA interactions. (D) Genes involved in the ceRNA network were clustered using KEGG pathway analysis. Squares indicate miRNAs, circles indicate coding genes, and rhombuses indicate lncRNAs. Red indicates upregulation, and blue indicates downregulation (P12/P4). Black arrows indicate the key lncRNAs.


### Quantitative real-time PCR

Total RNA was isolated using TRIzol reagent (Invitrogen, Scotland) and RNA Rapid Extraction Kit (Yishan, China) according to the manufacturer's instructions. RNA was quantified with a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, USA). The Prime ScriptRT reagent kit (Takara, Japan) was used to obtain cDNA. For miRNA assays, the reverse primer specific to miRNAs was provided in the Mir-X miRNA First-Strand Synthesis Kit (TaKaRa, USA), and cDNA was synthesized according to the manufacturer's instructions. For circRNAs, total RNA was digested by RNase R (GENESEED, China) or not according to the manufacturer's instructions. The circRNA real-time PCR reagent kit (GENESEED, China) was used to obtain cDNA. The cycling parameters were as follows: 10 min at 25°C followed by 30 min at 42°C and 5 min at 85°C. Specific divergent primers

spanning the back-splice junction sites of circRNAs were designed. qPCR was performed on an ABI PRISM 7700HT Sequence Detection System Instrument (Applied Biosystems, Germany) using SYBR Premix Ex Taq (TaKaRa). The cycling parameters were as follows: 30 s at 95°C followed by 40 cycles of 5 s at 95°C and 20 s at 60°C. Relative changes in RNA levels were assessed using the  $2^{-\Delta\Delta Ct}$  method and normalized to the levels of GAPDH or U6. The sequences of primers used in the qPCR assay are listed in Table S1.

### Statistical analysis

Statistical data are presented as the means  $\pm$  standard error of the mean. Student's *t* test was used for comparisons between two groups, or one-way analysis of variance in conjunction with a Bonferroni post-test was used for multiple comparisons using GraphPad Prism



**Figure 7. ceRNA network of circRNA-miRNA-mRNA interactions**

(A) Venn diagram showing the intersection of DE mRNAs and target mRNAs of DE miRNAs and the intersection of DE circRNAs and target circRNAs of DE miRNAs. (B and C) ceRNA regulatory network of circRNA-miRNA-mRNA interactions. Squares indicate miRNAs, circles indicate coding genes, and triangles indicate circRNAs. Red indicates upregulation, and blue indicates downregulation (P12/P4). Black arrows indicate the key circRNAs.

5 software. Spearman correlation was used to determine the relationship between lncRNAs and their target genes. p values < 0.05 were considered significant.

**Data availability statement**


The sequencing data analyzed in this study have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO: GSE178514 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE178514>).

**SUPPLEMENTAL INFORMATION**

Supplemental information can be found online at <https://doi.org/10.1016/j.omtn.2021.08.013>.

**ACKNOWLEDGMENTS**

The authors thank American Journal Experts for providing English language editing of the manuscript. This study was supported by the National Natural Science Foundation of China



**Figure 8. Validation of the key RNAs**

(A–D) Comparison of  $\log_2FC$  in eight DE miRNAs (A), eight DE mRNAs (B), eight lncRNAs (C), and six circRNAs (D) between RNA-seq and quantitative real-time PCR.  $n = 3$  MSCs per passage in RNA-seq.  $n = 10$  per passage in quantitative real-time PCR. (E) Schematic illustration showed the circularization of SERPINE2 exons 3–4, which resulted in the formation of circ\_0005773 (black arrow). Sanger sequencing confirmed the back-splice junction sites of circ\_0005773. Red arrow represents head-to-tail circ\_0005773 splicing sites. (F) The expression of circ\_0005773 and SERPINE2 mRNA in MSCs treated with or without RNase R was detected by quantitative real-time PCR. The relative levels of circ\_0005773 and SERPINE2 mRNA were normalized to the values measured for mock treatment.  $n = 10$  MSCs. (G–I) qPCR validation of the expression levels of circ\_0005773 (G), miR-17-5p (H), and LIF (I). Data are presented as the means  $\pm$  SEM. \* $p < 0.05$ , \*\* $p < 0.01$ . FC, fold change.  $n = 10$  MSCs per passage.

(31700884, 81672097), the Key-Area Research and Development Program of Guangdong Province (2019B020236001), and the Shenzhen Key Laboratory of Ankylosing Spondylitis (ZDSYS2019092092851024).

#### AUTHOR CONTRIBUTIONS

S.W., Z.W., and H. Su designed the study, performed the experiments, and analyzed the data; Y.W. and H. Shen revised the manuscript; M.M., X.W., and F.C. collected the data; G.Y., W.Y., S.C., R.M.,



W.D., P.F., and C.Z. contributed the reagents/materials/analysis tools; and S.W., Z.W., and H. Shen wrote the manuscript. All authors read and approved the final manuscript.

## DECLARATION OF INTERESTS

The authors declare no competing interests.

## REFERENCES

- Song, N., Scholtemeijer, M., and Shah, K. (2020). Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. *Trends Pharmacol. Sci.* *41*, 653–664.
- Musina, R.A., Bekchanova, E.S., and Sukhikh, G.T. (2005). Comparison of mesenchymal stem cells obtained from different human tissues. *Bull. Exp. Biol. Med.* *139*, 504–509.
- Paniushin, O.V., Domaratskaia, E.I., and Starostin, V.I. (2006). [Mesenchymal stem cells: sources, phenotype, and differentiation potential]. *Izv. Akad. Nauk Ser. Biol.* *1*, 6–25.
- Ceccarelli, S., Pontecorvi, P., Anastasiadou, E., Napoli, C., and Marchese, C. (2020). Immunomodulatory Effect of Adipose-Derived Stem Cells: The Cutting Edge of Clinical Application. *Front. Cell Dev. Biol.* *8*, 236.
- Wang, Y., Zhang, Z., Chi, Y., Zhang, Q., Xu, F., Yang, Z., Meng, L., Yang, S., Yan, S., Mao, A., et al. (2013). Long-term cultured mesenchymal stem cells frequently develop genomic mutations but do not undergo malignant transformation. *Cell Death Dis.* *4*, e950.
- Saeedi, P., Halabian, R., and Imani Fooladi, A.A. (2019). A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies. *Stem Cell Investig.* *6*, 34.
- Wang, P., Li, Y., Huang, L., Yang, J., Yang, R., Deng, W., Liang, B., Dai, L., Meng, Q., Gao, L., et al. (2014). Effects and safety of allogenic mesenchymal stem cell intravenous infusion in active ankylosing spondylitis patients who failed NSAIDs: a 20-week clinical trial. *Cell Transplant.* *23*, 1293–1303.
- Galipeau, J., and Sensebé, L. (2018). Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. *Cell Stem Cell* *22*, 824–833.
- Shi, Y., Wang, Y., Li, Q., Liu, K., Hou, J., Shao, C., and Wang, Y. (2018). Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. *Nat. Rev. Nephrol.* *14*, 493–507.
- Wagner, W., Horn, P., Castoldi, M., Diehlmann, A., Bork, S., Saffrich, R., Benes, V., Blake, J., Pfister, S., Eckstein, V., and Ho, A.D. (2008). Replicative senescence of mesenchymal stem cells: a continuous and organized process. *PLoS ONE* *3*, e2213.
- Baxter, M.A., Wynn, R.F., Jowitt, S.N., Wraith, J.E., Fairbairn, L.J., and Bellantuono, I. (2004). Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. *Stem Cells* *22*, 675–682.
- Fu, X., Xu, B., Jiang, J., Du, X., Yu, X., Yan, Y., Li, S., Inglis, B.M., Ma, H., Wang, H., et al. (2020). Effects of cryopreservation and long-term culture on biological characteristics and proteomic profiles of human umbilical cord-derived mesenchymal stem cells. *Clin. Proteomics* *17*, 15.
- Yang, Y.K., Ogando, C.R., Wang See, C., Chang, T.Y., and Barabino, G.A. (2018). Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro. *Stem Cell Res. Ther.* *9*, 131.
- de Witte, S.F.H., Lambert, E.E., Merino, A., Strini, T., Douben, H.J.C.W., O'Flynn, L., Elliman, S.J., de Klein, A.J.E.M.M., Newsome, P.N., Baan, C.C., and Hoogduijn, M.J. (2017). Aging of bone marrow- and umbilical cord-derived mesenchymal stromal cells during expansion. *Cytotherapy* *19*, 798–807.
- Ruparel, N.B., de Almeida, J.F.A., Henry, M.A., and Diogenes, A. (2013). Characterization of a stem cell of apical papilla cell line: effect of passage on cellular phenotype. *J. Endod.* *39*, 357–363.
- Wagner, W., Bork, S., Horn, P., Kronic, D., Walenda, T., Diehlmann, A., Benes, V., Blake, J., Huber, F.X., Eckstein, V., et al. (2009). Aging and replicative senescence have related effects on human stem and progenitor cells. *PLoS ONE* *4*, e5846.
- Anastasiadou, E., Faggioni, A., Trivedi, P., and Slack, F.J. (2018). The Nefarious Nexus of Noncoding RNAs in Cancer. *Int. J. Mol. Sci.* *19*, 2072.
- Anastasiadou, E., Jacob, L.S., and Slack, F.J. (2018). Non-coding RNA networks in cancer. *Nat. Rev. Cancer* *18*, 5–18.
- Zhuang, Z., Jia, L., Li, W., and Zheng, Y. (2021). The emerging roles of circular RNAs in regulating the fate of stem cells. *Mol. Cell. Biochem.* *476*, 231–246.
- Xie, Z.Y., Wang, P., Wu, Y.F., and Shen, H.Y. (2019). Long non-coding RNA: The functional regulator of mesenchymal stem cells. *World J. Stem Cells* *11*, 167–179.
- Puvvula, P.K. (2019). LncRNAs Regulatory Networks in Cellular Senescence. *Int. J. Mol. Sci.* *20*, 2615.
- Xia, W., Zhuang, L., Deng, X., and Hou, M. (2017). Long noncoding RNA-p21 modulates cellular senescence via the Wnt/ $\beta$ -catenin signaling pathway in mesenchymal stem cells. *Mol. Med. Rep.* *16*, 7039–7047.
- Bakopoulou, A., Apatzidou, D., Aggelidou, E., Gousopoulou, E., Leyhausen, G., Volk, J., Kritis, A., Koidis, P., and Geurtsen, W. (2017). Isolation and prolonged expansion of oral mesenchymal stem cells under clinical-grade, GMP-compliant conditions differentially affects “stemness” properties. *Stem Cell Res. Ther.* *8*, 247.
- Zhang, D., and Kilian, K.A. (2013). The effect of mesenchymal stem cell shape on the maintenance of multipotency. *Biomaterials* *34*, 3962–3969.
- Yu, Y., Park, Y.S., Kim, H.S., Kim, H.Y., Jin, Y.M., Jung, S.C., Ryu, K.H., and Jo, I. (2014). Characterization of long-term in vitro culture-related alterations of human tonsil-derived mesenchymal stem cells: role for CCN1 in replicative senescence-associated increase in osteogenic differentiation. *J. Anat.* *225*, 510–518.
- De Witte, S.F.H., Peters, F.S., Merino, A., Korevaar, S.S., Van Meurs, J.B.J., O'Flynn, L., Elliman, S.J., Newsome, P.N., Boer, K., Baan, C.C., and Hoogduijn, M.J. (2018). Epigenetic changes in umbilical cord mesenchymal stromal cells upon stimulation and culture expansion. *Cytotherapy* *20*, 919–929.
- Wiese, D.M., Ruttan, C.C., Wood, C.A., Ford, B.N., and Braid, L.R. (2019). Accumulating Transcriptome Drift Precedes Cell Aging in Human Umbilical Cord-Derived Mesenchymal Stromal Cells Serially Cultured to Replicative Senescence. *Stem Cells Transl. Med.* *8*, 945–958.
- Peffer, M.J., Collins, J., Fang, Y., Goljanek-Whysall, K., Rushton, M., Loughlin, J., Proctor, C., and Clegg, P.D. (2016). Age-related changes in mesenchymal stem cells identified using a multi-omics approach. *Eur. Cell. Mater.* *31*, 136–159.
- Bellay, I.H., Catalano, J.G., Lababidi, S., Yang, A.X., Lo Surdo, J.L., Bauer, S.R., and Puri, R.K. (2014). Gene markers of cellular aging in human multipotent stromal cells in culture. *Stem Cell Res. Ther.* *5*, 59.
- Cai, J., Miao, X., Li, Y., Smith, C., Tsang, K., Cheng, L., and Wang, Q.F. (2014). Whole-genome sequencing identifies genetic variances in culture-expanded human mesenchymal stem cells. *Stem Cell Reports* *3*, 227–233.
- Neri, S., and Borzi, R.M. (2020). Molecular Mechanisms Contributing to Mesenchymal Stromal Cell Aging. *Biomolecules* *10*, 340.
- Lavini-Ramos, C., Silva, H.M., Soares-Schanoski, A., Monteiro, S.M., Ferreira, L.R.P., Pacanaro, A.P., Gomes, S., Batista, J., Faé, K., Kalil, J., and Coelho, V. (2017). MMP9 integrates multiple immunoregulatory pathways that discriminate high suppressive activity of human mesenchymal stem cells. *Sci. Rep.* *7*, 874.
- Krupa, A., Fol, M., Dziadek, B.R., Kepka, E., Wojciechowska, D., Brzostek, A., Torzewska, A., Dziadek, J., Baughman, R.P., Griffith, D., and Kurdowska, A.K. (2015). Binding of CXCL8/IL-8 to Mycobacterium tuberculosis Modulates the Innate Immune Response. *Mediators Inflamm.* *2015*, 124762.
- Cen, S., Wang, P., Xie, Z., Yang, R., Li, J., Liu, Z., Wang, S., Wu, X., Liu, W., Li, M., et al. (2019). Autophagy enhances mesenchymal stem cell-mediated CD4<sup>+</sup> T cell migration and differentiation through CXCL8 and TGF- $\beta$ 1. *Stem Cell Res. Ther.* *10*, 265.
- Kortlever, R.M., Higgins, P.J., and Bernards, R. (2006). Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. *Nat. Cell Biol.* *8*, 877–884.
- Jin, H., Choung, H.W., Lim, K.T., Jin, B., Jin, C., Chung, J.H., and Choung, P.H. (2015). Recombinant Human Plasminogen Activator Inhibitor-1 Promotes Cementogenic Differentiation of Human Periodontal Ligament Stem Cells. *Tissue Eng. Part A* *21*, 2817–2828.
- Yang, F., Wu, R., Jiang, Z., Chen, J., Nan, J., Su, S., Zhang, N., Wang, C., Zhao, J., Ni, C., et al. (2018). Leptin increases mitochondrial OPA1 via GSK3-mediated OMA1

- ubiquitination to enhance therapeutic effects of mesenchymal stem cell transplantation. *Cell Death Dis.* 9, 556.
38. Coppé, J.P., Desprez, P.Y., Krtolica, A., and Campisi, J. (2010). The senescence-associated secretory phenotype: the dark side of tumor suppression. *Annu. Rev. Pathol.* 5, 99–118.
  39. Della Bella, E., Menzel, U., Basoli, V., Tourbier, C., Alini, M., and Stoddart, M.J. (2020). Differential Regulation of circRNA, miRNA, and piRNA during Early Osteogenic and Chondrogenic Differentiation of Human Mesenchymal Stromal Cells. *Cells* 9, 398.
  40. Batista, P.J., and Chang, H.Y. (2013). Long noncoding RNAs: cellular address codes in development and disease. *Cell* 152, 1298–1307.
  41. He, Y., Luo, J., Chen, Y., Zhou, X., Yu, S., Jin, L., Xiao, X., Jia, S., and Liu, Q. (2018). ARHGAP18 is a novel gene under positive natural selection that influences HbF levels in  $\beta$ -thalassaemia. *Mol. Genet. Genomics* 293, 207–216.
  42. Peck, J., Douglas, G., 4th, Wu, C.H., and Burbelo, P.D. (2002). Human RhoGAP domain-containing proteins: structure, function and evolutionary relationships. *FEBS Lett.* 528, 27–34.
  43. Thomson, D.W., and Dinger, M.E. (2016). Endogenous microRNA sponges: evidence and controversy. *Nat. Rev. Genet.* 17, 272–283.
  44. Silverman, E.K., Schmidt, H.H.H.W., Anastasiadou, E., Altucci, L., Angelini, M., Badimon, L., Balligand, J.L., Benincasa, G., Capasso, G., Conte, F., et al. (2020). Molecular networks in Network Medicine: Development and applications. *Wiley Interdiscip. Rev. Syst. Biol. Med.* 12, e1489.
  45. Li, M., Xie, Z., Cai, Z., Su, F., Zheng, G., Li, J., Wang, S., Cen, S., Liu, W., Tang, S., et al. (2019). lncRNA-mRNA expression profiles and functional networks of mesenchymal stromal cells involved in monocyte regulation. *Stem Cell Res. Ther.* 10, 207.
  46. Zhou, J., Nie, H., Liu, P., Wang, Z., Yao, B., and Yang, L. (2019). Down-regulation of miR-339 promotes differentiation of BMSCs and alleviates osteoporosis by targeting DLX5. *Eur. Rev. Med. Pharmacol. Sci.* 23, 29–36.
  47. Chen, Y.S., Kang, X.R., Zhou, Z.H., Yang, J., Xin, Q., Ying, C.T., Zhang, Y.P., and Tao, J. (2020). MiR-1908/EXO1 and MiR-203a/FOS, regulated by scd1, are associated with fracture risk and bone health in postmenopausal diabetic women. *Aging (Albany NY)* 12, 9549–9584.
  48. Yang, H., Cao, Y., Zhang, J., Liang, Y., Su, X., Zhang, C., Liu, H., Han, X., Ge, L., and Fan, Z. (2020). DLX5 and HOXC8 enhance the chondrogenic differentiation potential of stem cells from apical papilla via LINC01013. *Stem Cell Res. Ther.* 11, 271.
  49. Liu, Y.Y., Tanikawa, C., Ueda, K., and Matsuda, K. (2019). INKA2, a novel p53 target that interacts with the serine/threonine kinase PAK4. *Int. J. Oncol.* 54, 1907–1920.
  50. Akiyama, H., Iwasaki, Y., Yamada, S., Kamiguchi, H., and Sakakibara, S.I. (2020). Control of cell migration by the novel protein phosphatase-2A interacting protein inka2. *Cell Tissue Res.* 380, 527–537.
  51. Lei, B., Yu, L., Jung, T.A., Deng, Y., Xiang, W., Liu, Y., and Qi, S. (2018). Prospective Series of Nine Long Noncoding RNAs Associated with Survival of Patients with Glioblastoma. *J. Neurol. Surg. A Cent. Eur. Neurosurg.* 79, 471–478.
  52. Li, H., Chi, X., Li, R., Ouyang, J., and Chen, Y. (2020). A Novel lncRNA, AK130181, Contributes to HIV-1 Latency by Regulating Viral Promoter-Driven Gene Expression in Primary CD4<sup>+</sup> T Cells. *Mol. Ther. Nucleic Acids* 20, 754–763.
  53. Huang, J., Xie, N., Huang, H., Yao, J., and Hu, W. (2018). Long noncoding RNA STXBP5-AS1 inhibits cell proliferation, migration, and invasion via preventing the PI3K/AKT against STXBP5 expression in non-small-cell lung carcinoma. *J. Cell. Biochem.* 2018, 18.
  54. Meng, Q., Wang, X., Xue, T., Zhao, Q., Wang, W., and Zhao, K. (2020). Long non-coding RNA MIR99AHG promotes gastric cancer progression by inducing EMT and inhibiting apoptosis via miR577/FOXP1 axis. *Cancer Cell Int.* 20, 414.
  55. Shen, Q., Sun, Y., and Xu, S. (2020). LINC01503/miR-342-3p facilitates malignancy in non-small-cell lung cancer cells via regulating LASP1. *Respir. Res.* 21, 235.
  56. Bavelloni, A., Ramazzotti, G., Poli, A., Piazzzi, M., Focaccia, E., Blalock, W., and Faenza, I. (2017). MiRNA-210: A Current Overview. *Anticancer Res.* 37, 6511–6521.
  57. Ren, S., Lin, P., Wang, J., Yu, H., Lv, T., Sun, L., and Du, G. (2020). Circular RNAs: Promising Molecular Biomarkers of Human Aging-Related Diseases via Functioning as an miRNA Sponge. *Mol. Ther. Methods Clin. Dev.* 18, 215–229.
  58. Hansen, T.B., Jensen, T.I., Clausen, B.H., Bramsen, J.B., Finsen, B., Damgaard, C.K., and Kjems, J. (2013). Natural RNA circles function as efficient microRNA sponges. *Nature* 495, 384–388.
  59. Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., Maier, L., Mackowiak, S.D., Gregersen, L.H., Munschauer, M., et al. (2013). Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature* 495, 333–338.
  60. Shen, S., Wu, Y., Chen, J., Xie, Z., Huang, K., Wang, G., Yang, Y., Ni, W., Chen, Z., Shi, P., et al. (2019). CircSERPINE2 protects against osteoarthritis by targeting miR-1271 and ETS-related gene. *Ann. Rheum. Dis.* 78, 826–836.
  61. Zhang, Q., Qiao, X., and Xia, W. (2020). CircSERPINE2 weakens IL-1 $\beta$ -caused apoptosis and extracellular matrix degradation of chondrocytes by regulating miR-495/TGFBR2 axis. *Biosci. Rep.* 40, BSR20201601.
  62. Ma, Y., Shan, Z., Liu, Y., Shao, H., Xin, Y., He, K., Jiang, S., and Wang, Y. (2020). CircTHBS1 targeting miR-211/CCND2 pathway to promote cell proliferation and migration potential in primary cystitis glandularis cells. *Biosci Rep* 41, BSR20201164.
  63. Chen, H., Wu, G., Chen, G., Wang, W., and Ruan, F. (2020). Circular RNA THBS1 promotes proliferation and apoptosis of non-small cell lung cancer cells by sponging miR-129-5p and regulating SOX4 expression. *J. BUON* 25, 1721–1727.
  64. Zang, Y., Li, J., Wan, B., and Tai, Y. (2020). circRNA circ-CCND1 promotes the proliferation of laryngeal squamous cell carcinoma through elevating CCND1 expression via interacting with HuR and miR-646. *J. Cell. Mol. Med.* 24, 2423–2433.
  65. Cawthon, R.M. (2002). Telomere measurement by quantitative PCR. *Nucleic Acids Res.* 30, e47.
  66. Li, J.H., Liu, S., Zhou, H., Qu, L.H., and Yang, J.H. (2014). starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. *Nucleic Acids Res.* 42, D92–D97.

**Supplemental information**

**Effects of long-term culture on the biological characteristics and RNA profiles of human bone-marrow-derived mesenchymal stem cells**

**Shan Wang, Ziming Wang, Hongjun Su, Finglei Chen, Mengjun Ma, Wenhui Yu, Guiwen Ye, Shuizhong Cen, Rujia Mi, Xiaohua Wu, Wen Deng, Pei Feng, Chenying Zeng, Huiyong Shen, and Yanfeng Wu**

**Table S1. Quantitative Profiles of the Cell Cycle Study of MSCs at P4, P6, P8, P10 and P12  
(n=9, means ± SD)**

Percent of Cells in the Cell Cycle	P4	P6	P8	P10	P12
Percent of G1 cells	61.42±7.33	61.76±7.17	66.88±9.07	65.53±5.00	59.56±9.74
Percent of S+G2/M cells	26.72±3.54	19.39±1.82	14.16±2.51	10.86±2.19	7.51±1.58
Percent of S cells	20.9±2.52	15.54±1.82	12.08±3.05	9.28±2.29	6.68±1.78
Percent of G2/M cells	5.82±2.32	3.85±1.60	2.35±0.73	1.58±0.62	0.84±0.46

**Table S2. Top 10 Terms with the Largest Significant Differences in the GO Biological Process****Analysis of DE mRNAs Related to Proliferation**

Term	Count	Rich Ratio	<i>p</i> Value	Gene
Positive regulation of cell proliferation	21	0.029577	3.90E-10	LEP, GREM1, S1PR1, LIF, EPGN, TNC, SOX4, S1PR3, FGF2, CCND1, THBS1, ADM, EDN1, PTN, STAT1, DMD, CXCL12, RUNX2, GPNMB, IGF2, GRK5
Positive regulation of apoptotic process	16	0.034858	3.68E-16	CLU, FGD4, FANK1, ARHGEF3, SOX4, MMP9, ANKRD1, EVI2A, ADM, PTN, BNIP3, NGF, PYCARD, PNMA2, LDHA, SFRP4
Heart development	10	0.031949	5.60E-10	SOX4, CRIP1, GLI3, EVI2A, ADM, EDN1, PTN, ZFP36L1, DVL2, HEG1
Response to hypoxia	9	0.038961	7.83E-10	LEP, EVI2A, CAV1, THBS1, ADM, EDN1, CXCL12, BNIP3, LDHA
Cellular response to transforming growth factor beta stimulus	6	0.075	1.29E-08	TINAGL1, ANKRD1, CAV1, CLEC3B, EDN1, ZFP36L1
Telomere organization	4	0.285714	1.42E-08	HIST1H4A, HIST1H3I, HIST1H3H, HIST1H3A
Vasculogenesis	6	0.073171	1.50E-08	TEAD2, CAV1, ADM, ZFP36L1, EPHA2, HEG1
Negative regulation of apoptotic process	12	0.015287	3.55E-08	LEP, FANK1, EPHB2, MMP9, GLI3, EVI2A, THBS1, COMP, BNIP3, NGF, SH3D21, EPHA2
Negative regulation of cell death	6	0.063158	3.66E-08	CLU, TEAD2, SOX4, FGF2, BNIP3, WISP2
DNA replication-dependent nucleosome assembly	4	0.181818	1.03E-07	HIST1H4A, HIST1H3I, HIST1H3H, HIST1H3A
Chromatin silencing at rDNA	4	0.166667	1.49E-07	HIST1H4A, HIST1H3I, HIST1H3H, HIST1H3A

**Table S3. Top 10 Terms with the Largest Significant Differences in the GO Biological Process****Analysis of DE mRNAs Related to Differentiation**

Term	Count	Rich Ratio	<i>p</i> Value	Gene
Ossification	15	0.12605	1.63E-16	TMEM119, LRRC17, IFITM1, MMP9, STC1, ACP5, MMP16, TWIST1, CLEC3B, PTN, COMP, RUNX2, KAZALD1, MGP, IGF2
Angiogenesis	21	0.058496	8.62E-16	LEP, NDNF, GREM1, ANGPTL4, S1PR1, NRP2, SLC38A1, EPGN, CXCL8, EPHB2, EGFL7, ADGRA2, SERPINE1, JAG1, TGFBI, FZD8, CAV1, CCBE1, NRCAM, EPHA2, COL4A1
Cell differentiation	32	0.027515	3.14E-14	TMEM119, NOTCH3, HERC4, ANGPTL4, SH3PXD2B, GLIS2, EPHB2, EGFL7, SOX4, OSR1, TWIST1, CAV1, NR1H3, CAV2, DMD, BEX1, SERPINE2, TENM4, RUNX2, EFNA5, ZNF521, KAZALD1, MGP, CADM1, MDK, EPHA2, PTPRU, RARRES2, SFRP4, DCLK1, STMN1, PSMB8
Osteoblast differentiation	10	0.070423	6.96E-09	TMEM119, RRAS2, LRRC17, TNC, EVI2A, TWIST1, RUNX2, GPNMB, EPHA2, IGF2
Multicellular organism development	32	0.025157	3.59E-13	EYA1, NOTCH3, ANGPTL4, GLIS2, LIF, EPHB2, EGFL7, JAG1, TWIST1, GDF6, FZD8, DKK1, CCBE1, NR1H3, SERPINE2, ZFP36L1, DVL2, TENM4, KIAA1217, EYA2, EFNA5, ZNF521, SERPINF1, KAZALD1, MGP, CADM1, EPHA2, IGF2, HEG1, SFRP4, DCLK1, STMN1
Skeletal system development	14	0.075676	2.21E-12	SH3PXD2B, FAM20C, NPR3, SOX4, PAPSS2, MMP9, ANKH, EDN1, AEBP1, COMP, RUNX2, TNFRSF11B, EPHA2, IGF2
Vasculogenesis	6	0.073171	1.50E-08	TEAD2, CAV1, ADM, ZFP36L1, EPHA2, HEG1
Extracellular matrix organization	14	0.050909	4.42E-10	NDNF, RECK, TNC, FGF2, MMP9, SERPINE1, EVI2A, TGFBI, THBS1, COMP, TNFRSF11B, COL14A1, KAZALD1, COL4A1
Regulation of signalling receptor activity	17	0.037862	5.32E-10	LEP, NBL1, LIF, CXCL8, SERPINE1, STC1, JAG1, GDF6, DKK1, GDF5, ADM, EDN1, PTN, CXCL12, NGF, GPNMB, IGF2
Cell adhesion	21	0.027027	1.96E-09	S1PR1, RGMB, NRP2, TNC, EGFL7, JUP, THBS2, LOXL2, TGFBI, THBS1, CDH6, CXCL12, PERP, THBS3, COMP, COL14A1, CADM1, NRCAM, GPNMB, EPHA2, PTPRU

**Table S4. Top 10 Terms with the Largest Significant Differences in the GO Biological Process  
Analysis of DE mRNAs Related to the Immune Response**

Term	Count	Rich Ratio	<i>p</i> Value	Gene
Immune system process	20	0.038685	1.24E-13	ULBP2, CLU, TINAGL1, GSDMD, CD74, SAMHD1, IFITM1, PSMB9, C1S, C1R, ECSIT, HLA-B, CD55, SPON2, CFI, SLC7A8, CFB, PYCARD, CADM1, PSMB8
Positive regulation of apoptotic process	16	0.034858	2.02E-10	CLU, FGD4, FANK1, ARHGEF3, SOX4, MMP9, ANKRD1, EVI2A, ADM, PTN, BNIP3, NGF, PYCARD, PNMA2, LDHA, SFRP4
Immune response	17	0.028428	1.18E-09	ULBP2, TINAGL1, LIF, CXCL8, CD74, SAMHD1, CRIP1, GBP2, SUSP2, C1R, THBS1, HLA-B, 105369230, CXCL12, FCGRT, TNFRSF11B, COLEC12
Inflammatory response	16	0.030075	1.71E-09	MAP2K3, GSDMD, GGT5, CXCL8, S1PR3, MGLL, PTX3, CHI3L1, PTGFR, THBS1, TNFRSF11B, PYCARD, SDC1, SELENOP, EPHA2, RARRES2
Response to glucocorticoid	8	0.096386	3.43E-09	IGFBP2, CCND1, ADM, TYMS, PAPP, SDC1, MDK, PTPRU
Response to hypoxia	11	0.047619	6.75E-09	LEP, ANGPTL4, EVI2A, CAV1, THBS1, ADM, EDN1, CXCL12, BNIP3, SOD3, LDHA
Innate immune response	17	0.025223	7.06E-09	CLU, TINAGL1, GSDMD, SAMHD1, IFITM1, PTX3, C1S, C1R, ECSIT, HLA-B, CD55, SPON2, CFI, CFB, PYCARD, COLEC12, RARRES2
Cellular response to hypoxia	8	0.055172	2.76E-07	NDNF, ANKRD1, TWIST1, STC2, EDN1, PTN, ZFP36L1, BNIP3
Regulation of complement activation	7	0.067961	3.86E-07	CLU, C1S, C1R, CD55, CFI, CFB, CPNE2
Cellular response to interleukin-1	7	0.06422	5.68E-07	TFPI, CXCL8, ANKRD1, GBP2, CHI3L1, EDN1, PYCARD

**Table S5. Characteristics of the circRNAs Involved in the Prediction ceRNA Network**

circBankID	circbaseID	Position	Stran SplicedSe			Gene Symbol
			d	qLength	BestTranscript	
hsa_circTHBS2_011	hsa_circ_0078715	chr6:169632074-169633112	-	500	NM_003247	THBS2
hsa_circTHBS2_016	hsa_circ_0078711	chr6:169626274-169629774	-	387	NM_003247	THBS2
hsa_circTHBS1_125	hsa_circ_0034540	chr15:39885597-39885869	+	272	NM_003246	THBS1
hsa_circTHBS1_055	hsa_circ_0034470	chr15:39877670-39879721	+	268	NM_003246	THBS1
hsa_circTHBS1_081	hsa_circ_0034496	chr15:39881159-39882224	+	500	NM_003246	THBS1
hsa_circTHBS1_108	hsa_circ_0034523	chr15:39883391-39885428	+	742	NM_003246	THBS1
hsa_circTHBS1_022	hsa_circ_0034437	chr15:39875817-39876388	+	276	NM_003246	THBS1
hsa_circTHBS1_086	hsa_circ_0034501	chr15:39881159-39886397	+	1720	NM_003246	THBS1
hsa_circTHBS1_058	hsa_circ_0034473	chr15:39879547-39880419	+	351	NM_003246	THBS1
hsa_circTHBS1_023	hsa_circ_0034438	chr15:39875817-39876623	+	399	NM_003246	THBS1
hsa_circTHBS1_093	hsa_circ_0034508	chr15:39881402-39886397	+	1592	NM_003246	THBS1
hsa_circTHBS1_075	hsa_circ_0034490	chr15:39880800-39882224	+	600	NM_003246	THBS1
hsa_circTHBS1_115	hsa_circ_0034530	chr15:39883705-39886397	+	952	NM_003246	THBS1
hsa_circTHBS1_001	hsa_circ_0034417	chr15:39873279-39874125	+	246	NM_003246	THBS1
hsa_circTHBS1_033	hsa_circ_0034448	chr15:39876188-39876623	+	323	NM_003246	THBS1
hsa_circTHBS1_012	hsa_circ_0034428	chr15:39874029-39882224	+	2174	NM_003246	THBS1
hsa_circTHBS1_096	hsa_circ_0034511	chr15:39882005-39883551	+	487	NM_003246	THBS1
hsa_circTHBS1_119	hsa_circ_0034534	chr15:39884768-39885869	+	735	NM_003246	THBS1
hsa_circTHBS1_048	hsa_circ_0034463	chr15:39876500-39879721	+	391	NM_003246	THBS1
hsa_circTHBS1_107	hsa_circ_0034522	chr15:39883391-39885003	+	514	NM_003246	THBS1
hsa_circTHBS1_089	hsa_circ_0034504	chr15:39881402-39882224	+	372	NM_003246	THBS1
hsa_circTHBS1_080	hsa_circ_0034495	chr15:39881159-39881555	+	281	NM_003246	THBS1
hsa_circTHBS1_034	hsa_circ_0034449	chr15:39876188-39877764	+	417	NM_003246	THBS1
hsa_circTHBS1_105	hsa_circ_0034520	chr15:39882716-39886397	+	1220	NM_003246	THBS1
hsa_circTHBS1_008	hsa_circ_0034424	chr15:39874029-39874953	+	656	NM_003246	THBS1
hsa_circTHBS1_050	hsa_circ_0034465	chr15:39876500-39882224	+	1242	NM_003246	THBS1
hsa_circTHBS1_109	hsa_circ_0034524	chr15:39883391-39885869	+	1014	NM_003246	THBS1
hsa_circTHBS1_099	hsa_circ_0034514	chr15:39882005-39886397	+	1439	NM_003246	THBS1
hsa_circTHBS1_065	hsa_circ_0034480	chr15:39880242-39880900	+	351	NM_003246	THBS1
hsa_circTHBS1_121	hsa_circ_0034536	chr15:39884768-39886641	+	973	NM_003246	THBS1
hsa_circTHBS1_117	hsa_circ_0034532	chr15:39884768-39885003	+	235	NM_003246	THBS1
hsa_circTHBS1_106	hsa_circ_0034521	chr15:39883391-39883824	+	279	NM_003246	THBS1
hsa_circTHBS1_123	hsa_circ_0034538	chr15:39885200-39885869	+	500	NM_003246	THBS1
hsa_circTHBS1_110	hsa_circ_0034525	chr15:39883391-39886641	+	1252	NM_003246	THBS1
hsa_circTHBS1_102	hsa_circ_0034517	chr15:39882716-39883824	+	387	NM_003246	THBS1
hsa_circTHBS1_118	hsa_circ_0034533	chr15:39884768-39885428	+	463	NM_003246	THBS1
hsa_circTHBS1_113	hsa_circ_0034528	chr15:39883705-39885003	+	354	NM_003246	THBS1
hsa_circTHBS1_120	hsa_circ_0034535	chr15:39884768-39886397	+	833	NM_003246	THBS1
hsa_circTHBS1_030	hsa_circ_0034445	chr15:39875817-39886397	+	2738	NM_003246	THBS1



hsa_circTHBS1_101	hsa_circ_0034516	chr15:39882716-39883551	+	268	NM_003246	THBS1
hsa_circTHBS1_126	hsa_circ_0034541	chr15:39885597-39886397	+	370	NM_003246	THBS1
hsa_circTGFB1_015	hsa_circ_0074046	chr5:135389631-135396625	+	780	NM_000358	TGFB1
hsa_circTGFB1_009	hsa_circ_0128030	chr5:135382539-135385269	+	454	NM_000358	TGFB1
hsa_circSERPINE2_006	hsa_circ_0058476	chr2:224849468-224856717	-	397	NM_006216	SERPINE2
hsa_circSERPINE2_004	hsa_circ_0005773	chr2:224856519-224863059	-	426	NM_006216	SERPINE2
hsa_circSERPINE1_013	hsa_circ_0081574	chr7:100778774-100780365	+	272	NM_000602	SERPINE1
hsa_circSERPINE1_010	hsa_circ_0081571	chr7:100776975-100780365	+	471	NM_000602	SERPINE1
hsa_circSERPINE1_007	hsa_circ_0081568	chr7:100773701-100775350	+	429	NM_000602	SERPINE1
hsa_circSERPINE1_001	hsa_circ_0081562	chr7:100770378-100771945	+	419	NM_000602	SERPINE1
hsa_circMT2A_002	hsa_circ_0039460	chr16:56642903-56643409	+	301	NM_005953	MT2A
hsa_circLOXL2_002	hsa_circ_0083670	chr8:23198504-23217778	-	388	NM_002318	LOXL2
hsa_circLOXL2_007	hsa_circ_0083666	chr8:23167180-23174627	-	410	NM_002318	LOXL2
hsa_circLOX_001	hsa_circ_0073686	chr5:121406188-121411236	-	391	NM_002317	LOX
hsa_circLDHA_006	hsa_circ_0006469	chr11:18422383-18425358	+	466	NM_001165414	LDHA
hsa_circLDHA_005	hsa_circ_0021450	chr11:18422383-18424560	+	348	NM_001165414	LDHA
hsa_circLDHA_009	hsa_circ_0021453	chr11:18424386-18425358	+	292	NM_001165414	LDHA
hsa_circLDHA_004	hsa_circ_0021449	chr11:18418365-18421095	+	268	NM_001165414	LDHA
hsa_circCD74_002	hsa_circ_0074531	chr5:149784242-149786887	-	500	NM_001025159	CD74
hsa_circCCND1_002	hsa_circ_0023304	chr11:69457798-69458759	+	376	NM_053056	CCND1


**Table S6. Primers Used for qPCR in the Validation**

Gene	Forward Primer (5'-3')	Reverse Primer (5'-3')
GAPDH	GGATGCAGGGATGATGTTCC	TGCACCACCAACTGCTTAG
U6	CTCGCTTCGGCAGCACAA	AACGCTTCACGAATTTGCGT
miR-1908-5p	CGGCGGGGACGGCGATTGGTC	CAGTGCCTGTCGTGGAGT
miR-16-5p	GGGTAGCAGCACGTAAATA	CAGTGCCTGTCGTGGAGT
miR-122-5p	GGGTGGAGTGTGACAATGG	CAGTGCCTGTCGTGGAGT
miR-193a-3p	GGGAACTGGCCTACAAAGT	CAGTGCCTGTCGTGGAGT
miR-199b-5p	CCAGTGTTTAGACTATCTGTTC	CAGTGCCTGTCGTGGAGT
miR-339-5p	TCCCTGTCCTCCAGGAGCT	CAGTGCCTGTCGTGGAGT
miR-210-5p	GGGAGCCCCCTGCCACCCG	CAGTGCCTGTCGTGGAGT
miR-431-5p	GGGUGUCUUGCAGGCCGU	CAGTGCCTGTCGTGGAGT
miR-17-5p	GGGCAAAGUGCUUACAGUGC	CAGTGCCTGTCGTGGAGT
miR-451a	AAACCGTTACCATTACTGAGTT	CAGTGCCTGTCGTGGAGT
COMP	GGCCCTGCATAGGGAATTAGA	TGTCCTCTGACATCCAACCTC
STC1	CACGAGCTGACTTCAACAGGA	GGATGTGCGTTTGATGTGGG
ADAMTS1	TGCGACGCTGCTTCTATTCTG	CCTCGGTAGCCAAAGGCTC
INKA2	AAAGAATTCTCCATTATGACGATGGAGAGCAG	AAACTCGAGTCAGACCCAAACAGCTGTGTTA
CDH6	AGAACTTACCGCTACTTCTTGC	TGCCACATACTGATAATCGGA
SPON2	GGAGAGTCCATCTGTTCCGC	ATGCTGTAGTCGGAGCTATGC
STC2	GCGTGCAGGTTCAAGTGTGA	GGCCAGTCTCCCTACTGCT
SERPINE2	GGAAGGAACCATGAACTGGC	GGGGAGAGATCACGATGTTGT
LIF	CCAACGTGACGGACTTCCC	TACACGACTATGCGGTACAGC
PTN	GGAGCTGAGTGCAAGCAAAC	CTCGCTTCAGACTTCCAGTTC
RUNX2	CCGCCTCAGTGATTTAGGGC	GGGTCTGTAATCTGACTCTGTCC
GREM1	CGGAGCGCAAATACCTGAAG	GGTTGATGATGGTGCAGCTGT
DKK1	CCTTGAACCTCGGTTCTCAATTCC	CAATGGTCTGGTACTTATTCCCG
SERPINF1	GGAAATTCCCAGATGAGATCAGC	AGTCAAACCTTTGTTACCCACTGC
ANGPTL4	GGCTCAGTGGACTTCAACCG	CCGTGATGCTATGCACCTTCT
PLTP	AAGAGCGGATGGTGTATGTGG	ATGGGGAGTCAATCACTGCTG
MMP9	TGTACCGCTATGGTTACTCTCG	GGCAGGGACAGTTGCTTCT
CCND1	GCTGCGAAGTGGAACCATC	CCTCCTTCTGCACACATTTGAA
SERPINE1	AGTGGACTTTTCAGAGGTGGA	GCCGTTGAAGTAGAGGGCATT
NDUFA4L2	CCTGAGCCCCAATGACCAATA	TCTGGCCGGTCTTCTTCA
TINAGL1	ATGGGACCCACTCAGTCAAGA	GTTGGCCGCAGTCCAGTATTT
COLEC12	AATCCTTCGGTTACAAGCGGT	ACTGTGATTGTTAGCAAGGCAC
APOE	GTTGCTGGTCACATTCCTGG	GCAGGTAATCCCAAAAGCGAC
MDK	CGCGGTTCGCCAAAAGAAAG	TACTTGCAGTCGGCTCCAAAC
AEBP1	ACCCACACTGGACTACAATGA	GTTGGGGATCACGTAACCATC
MIR99AHG	AGATTGCCTGCCACACACAT	AAGTTTTCTGCATCCGTGCG
LINC01503	CTTCCCTGAGGACCATCTG	CAAAATCCGGTCTTCTGGA
ITGA6-AS1	AGGTGGCAACATCCCTACAC	GACCCAACAGGCATGAAGGTA
INKA2-AS1	ACATTCAGCCTGGACACCC	TGAAGGTCCTTTTCAGCTCCC
STXBP5-AS1	GAGATTTAGGTGGGGACGCTGC	AGGGACTTGCCTTGTCTGCTGAT

---


LOC102723409	CAGGAGCCCAGCAAGTGTCT	TGATAGGGAGCAAGCAGTTCG
LOC105747689	AATATGGGGCACCAACGGAG	GCAAGCTCCTCCACTGAACA
LINC02407	GATGAAAACGACATGCGTGACA	TTCACTGTCGGTCTCCCTCT
LOC105377378	TTGGATGGATGACTATTTCTGC	AGGGGAAGTGGTACAAAAGCA
BCYRN1	ATAGCTTGAGCCCAGGAGTT	GCTTTGAGGGAAGTTACGCTTAT
LINC00968	AGATGATGTCGCAAGGGTGG	GGCTCCACCTGAAGTTACCC
LINC01423	CAAGGTCCTGCTGTCTTTCCA	GATGGTAACACCCCATCTGCT
LINC01013	CATCCAGCAGTGCCCAAGTA	GCTCTCCTTTGTTCCAGGCT
circ_0078715	GGGAAGCAGGGGTTGGATAA	CTCATCTGCGGGGAGGACT
circ_0078711	TCATCACAGGCATCGCCAATC	GACGGTGTGGGGGATCACT
circ_0058476	ACCCTTGAAATACACTGCGT	CAGCACCAAGACCATAGACA
circ_0005773	TACCAACTCCACACCGGAAC	AAGAAACGCACTTTCGTGGC
circ_0081571	GTCATAGTCTCAGCCCGCAT	GTGAACTCAGCTGTGGGGTT
circ_0081562	GCAACGTGGTTTTCTCACCC	ACAGCTGTGCTCCTCATCAA
circ_0041340	CAGCATTCTCCTTCTCGGTGT	TACCATGGATGTCTGGGCTG

---



**Figure S1. Results of KEGG from GSEA.**

A.12 representative enriched senescence-related KEGG pathways from genes of P4 and P12. Normalized enrichment score (NES) and nominal p-value (NOM p-val) are shown.



**Figure S2. qPCR Validation**

A. Comparison of  $\log_2FC$  of mRNAs involved in important process and pathway between RNA-Seq and qRT-PCR. B. qPCR validation of the expression levels of some RNAs in MSCs at P4, P6, P8, P10 and P12 merging the RNA sequencing (RNA-seq) results in P4, P6 and P12. Data are presented as the means  $\pm$  SEM.  $n=3$  MSCs per passage in RNA-Seq.  $n=10$  per passage in qRT-PCR.